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ABSTRACT 
  
The success of scale up of antiretroviral therapy (ART) in low- and middle-income 
countries (LMICs) is in large part due to the introduction of a “public health approach” to 
access advocated by the World Health Organization (WHO) which emphasized 
standardized treatment regimens that could be purchased in large quantities and delivered 
at scale. In 2010 the WHO updated their global HIV treatment guidelines recommending 
the substitution of stavudine with tenofovir (both of which are members of the non-
nucleoside reverse transcriptase inhibitor (NRTI) class of drugs) in first-line antiretroviral 
therapy (ART). Given the size of treatment programs in sub-Saharan Africa, changing the 
NRTI used in first-line therapy for HIV could have a substantial impact on treatment 
outcomes. We conducted three prospective cohort studies using clinical datasets from 
several sub-Saharan African countries to answer questions surrounding the impacts of 
exposure to tenofovir in first-line therapy.  
The first study examines the frequency of stavudine use and single-drug substitutions 
(substituting the NRTI in first-line ART) in three regions in sub-Saharan Africa by 
calendar year, 2004–2014. We found a total of 33,441 (8.9%; 95% CI: 8.7–8.9%) single-
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drug substitutions occurred among 377,656 patients in the first 24 months on ART, close 
to 40% of which were amongst patients on stavudine. The decrease in single-drug 
substitutions corresponded with the phasing out of stavudine. We saw an 80% reduction 
in the risk of single-drug substitutions when comparing tenofovir to stavudine and close 
to a 70% reduction in the risk when comparing zidovudine to stavudine.  
The second study uses a regression discontinuity design to evaluate the impact of 
national HIV treatment guideline changes in South Africa and Zambia recommending 
tenofovir in first-line ART on treatment outcomes. We found that updated WHO 
guidelines increased the proportion of patients initiating tenofovir (risk difference (RD) 
(South Africa): 81%; 95% CI: 73%, 89%; RD (Zambia): 42%; 95% CI: 38%, 45%). 
Intent to treat estimates showed a decrease in single-drug substitutions in South Africa 
(RD: -15%; 95% CI: -18%, -12%) and Zambia (RD: -2.0%; 95% CI: -3.6%, -0.3%). In 
both countries, there was no effect on mortality, attrition or viral load failure (South 
Africa only).  
The third study investigates the effect of the 2012 tenofovir stock shortage in South 
Africa on provider and patient level outcomes, using data from four public-sector Right 
to Care clinics, two of which experienced a tenofovir stock shortage and two that did not.  
While imprecise, our results suggest a potential shift in how providers managed patients 
during the period of the shortage, mainly, a noticeable decrease in the average number of 
days between visits during the shortage compare to before or after at all four clinics and a 
significant difference in the proportion of patients missing visits. Difference-in-difference 
regression results showed a small, but significant, increase in the risk of missed visits 
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during the shortage compared to after (RD: 1.2%; 95% CI: 0.5%, 2.0%), mainly driven 
by ACTs clinic. No significant difference was seen in other outcomes.  
Great strides have been made to extend access to ART as well as increase the quality 
of the services provided to patients in sub-Saharan Africa. Continued access to and a 
consistent supply of tenofovir in this setting is necessary for patients to receive drugs that 
are comparable to those used for HIV treatment in high-income countries, as we show 
that phasing out of stavudine and for either zidovudine or tenofovir potentially reduced 
toxicities and potentially improved quality of life in multiple regions throughout sub-
Saharan Africa. While we show little effect on treatment outcomes when comparing 
patients accessing care and treatment during the shortage of tenofovir compared to those 
that did not, this most likely reflects the clinics’ ability to offset the crisis by continuing 
to initiate newly diagnosed and eligible patients on treatment and keep treatment 
experienced patients on their current regimen.  
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CHAPTER ONE 
 
Section One 
The HIV epidemic remains a major public health challenge, with over 33 million 
people infected worldwide [1]. At the end of 2012, 9.7 million people living with HIV 
had initiated antiretroviral therapy (ART) in LMICs (low-income countries defined as 
those with a gross national income per capita of $1,045 or less and middle-income 
countries are those with a gross national income per capita of more than $1,045 but less 
than $12,736 [1]) an increase of over 1.6 million from 2011, representing nearly 
exponential growth in access [1]. In sub-Saharan Africa roughly 55% of the 11.7 million 
people eligible for ART are currently receiving therapy [1].  
 
WHO 2004 ART Guidelines: A public health approach to HIV treatment  
The success of free, large scale access to ART in LMICs, which began in earnest 
in 2004, is in large part due to the introduction of a “public health approach” to access 
advocated by the World Health Organization (WHO) which emphasized standardized 
treatment regimens that could be purchased in large quantities and delivered at scale 
[2,3]. In deciding what drug regimens to recommend, the WHO considered efficacy, 
tolerability, cold chain requirements, drug availability and cost [4–14]. Accordingly, the 
2004 WHO treatment guidelines recommended first-line ART regimens including three 
drugs: two nucleoside reverse transcriptase inhibitors (NRTIs) (lamivudine and a choice 
of either stavudine or zidovudine), and a non-nucleoside reverse transcriptase inhibitors 
(NNRTIs)(either nevirapine or efavirenz) [2]. While the choice of stavudine or 
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zidovudine was left to each country to decide, because zidovudine was poorly tolerated 
and required more safety monitoring [2], stavudine became the NRTI of choice in first-
line ART for the majority of low- to middle-income countries. 
While not recommended in the 2004 WHO guidelines due to concerns over 
reports of associations with renal failure [15–17], the NRTI tenofovir was already 
preferred in first-line ART in resource-rich settings since 2002 [18,19]. In addition to the 
safety concerns, tenofovir’s limited availability and high cost [2] were significant barriers 
to large-scale implementation for low- to middle-income countries, and accordingly the 
WHO only recommended use of tenofovir in second-line treatment [2]. However, over 
time accumulating data demonstrated that stavudine was associated with severe side-
effects, including dyslipidemias, lipoatrophy and mitochondrial toxicities, notably 
peripheral neuropathy and lactic acidosis, in 5–20% of patients [20–24] making it a less 
attractive drug for large scale use. In 2009 the WHO recommended discontinuing 
stavudine for initial HIV treatment in favor of tenofovir [3,25]. 
 
WHO 2010 Guidelines: Replacement of stavudine with tenofovir in first-line ART 
In 2010, the WHO updated their treatment guidelines to include tenofovir in first-
line ART based on evidence suggesting that regimens containing tenofovir were 
comparable in terms of efficacy and had a better overall toxicity profile than stavudine-
based regimens [26,27]. Additionally, the price of tenofovir decreased sharply in 2009 
making it a more feasible choice for national programs [28]. By 2012, 67 out of 83 low- 
to middle-income countries had adopted the 2010 WHO guidelines and began the 
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transition away from stavudine for either tenofovir or zidovudine for all new initiates, 
patients showing signs of toxicity and those at high-risk for toxicity (e.g. patients with 
high BMI, those with low iron levels and older females) [3,25]. However, despite the 
commitment to the change, phase out of tenofovir has been slow, predominately due to 
insufficient financial resources needed for drug procurement. Currently an estimated 31% 
of adults in low- to middle-income countries are still being initiated on stavudine [29].  
Given the size of treatment programs in sub-Saharan Africa, changing the NRTI 
used in first-line therapy could have a substantial impact on treatment outcomes. It is 
therefore not only vital to evaluate the effect of the change in countries that substituted 
stavudine with tenofovir, but results of this study could provide a clearer picture of what 
is to come in countries that have yet to complete the transition to tenofovir in accordance 
with the WHO recommendations. To date, there has been no evaluation of the effect of 
the 2010 WHO policy change replacing stavudine with tenofovir in first-line therapy on 
treatment outcomes across multiple low- to middle-income countries. 
 
Regimen durability of first-line ART in low- and middle-income countries 
HIV treatment programs in most LMICs utilize twelve antiretrovirals (ARV) in 
three drug classes [3,25]. Since treatment options are limited and at least three drugs from 
two drug classes are typically needed for effectiveness, therapy options need to be 
maximized by decreasing rates of substituting individual drugs (typically for reasons of 
toxicity) within first-line therapy (referred to as ‘single-drug substitution‘) and reducing 
development of resistance and switching to more expensive second-line therapy. Since 
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there are fewer side-effects and drug toxicities associated with tenofovir than stavudine 
[18, 19] or zidovudine [2] it is hoped that the switch to tenofovir will be accompanied by 
an increase in the durability of first-line ART. 
Limited research has examined regimen durability (measured by the rate of 
single-drug substitutions) in relation to the WHO policy change recommending the 
substitution of stavudine with tenofovir in first-line ART. To date, several [30–38] 
observational studies set in low- to middle-income countries have compared single-drug 
substitutions (defined as changing one NRTI for another within first-line ART) amongst 
patients on tenofovir-based, stavudine-based and zidovudine-based regimens using 
routine clinical program data. All five studies found that those patients on stavudine and 
zidovudine were at increased risk of single-drug substitution compared to patients on 
tenofovir. All studies found that patients on tenofovir had about an 80% decrease in the 
risk of single-drug substitution (summary risk ratio (RR):0.21; 95% confidence interval 
(CI):0.20–0.22) compared to patients on stavudine [30–38], while patients on zidovudine, 
although at higher risk of single-drug substitutions compared to tenofovir, remained at 
lower risk of substitution compared to patients on stavudine (summary RR:0.31; 
95%CI:0.30–33) [30–35].  There have also been no randomized trials that specifically 
looked at the effect of stavudine or zidovudine compared to tenofovir use and regimen 
durability.  
 
Tenofovir drug shortages in South Africa 
Drug shortages in many low- to middle-income countries are common. Despite 
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being the wealthiest country in the region, South Africa has been no exception. In 
October 2012 a major shortage of tenofovir occurred and lasted for seven months [39] as 
a result of miscommunication between the Department of Health and pharmaceutical 
suppliers [39]. Many clinics suffered from either shortages or complete stock-outs of 
tenofovir. During this time clinicians were advised to initiate treatment naïve patients on 
stavudine and switch treatment experienced patients on tenofovir to stavudine with the 
expectation they would return to tenofovir when available. 
About 20% of health facilities throughout South Africa were estimated to have 
had either a complete stock-out or shortage of tenofovir [39]. The consequences and costs 
of these stock-outs have not been quantified but could be severe. A shortage of tenofovir 
would increase the use of more toxic drugs, stavudine [30–38] and zidovudine [30–35], 
ultimately decreasing the durability of first-line regimens [30–38] and increasing 
interruptions in therapy. We know of no other studies quantifying the effect of ARV 
shortages due to poor infrastructure in the health care system on patient-level outcomes in 
LMICs. 
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CHAPTER TWO 
 
While previous observational studies do suggest tenofovir and zidovudine are 
associated with fewer single-drug substitutions compared to stavudine [30–38], many had 
important limitations. Two studies [30, 31] had patient populations that initiated tenofovir 
prior to implementation of the 2010 WHO policy change. These patients would be more 
likely to have initiated tenofovir because of contraindications to stavudine or zidovudine 
leading to strong confounding by indication. Many of the studies were limited to single 
site comparisons [31, 32, 34] conducted in well-resourced clinics that may not be 
generalizable to national programs in resource constrained environments. We sought to 
use one of the largest HIV database in the world to assess whether or not the phasing out 
of stavudine in first-line ART in accordance with WHO 2010 policy decreased single-
drug substitutions in sub-Saharan Africa. This transition allows evaluation of the impact 
of a major policy change while accounting for secular trends in improvements in HIV 
treatment.   
These limitations combined with the WHO Global HIV drug resistance networks 
(WHO HIV ResNet) interest in empirical evidence examining the durability of first-line 
ART regimens in order to update WHO guidelines on safety monitoring of patients on 
treatment [40] only adds to the value of this analysis and its potential impact on policy. 
The opportunity to show the effects of tenofovir on regimen durability on a larger scale, 
across multiple LMICs that substituted stavudine with tenofovir (or zidovudine in the 
case of Mozambique) at different times, would provide strong evidence to evaluate 
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whether the effects observed in individual clinics is indeed a true effect of the WHO 
policy change.  
 
METHODS 
 
Cohort Description 
The International epidemiological Databases to Evaluate AIDS (IeDEA, 
www.iedea.org) is a world-wide National Institute of Health sponsored collaboration of 
HIV treatment cohorts. This study included cohorts from Southern Africa, East Africa 
and West Africa [41]. Data is collected on patients at the start of ART and at each follow-
up visit. Clinic information includes demographic, clinical and HIV regimen data. Before 
April 2010(2007 in Zambia), if a patient experienced side-effects or toxicities related to 
stavudine or zidovudine, and was not in need of second-line therapy, the recommendation 
was to substitute stavudine with either zidovudine, if no related anemia or neutropenia 
was present, or abacavir and to substitute zidovudine with either stavudine or abacavir 
[42–48]. After April 2010(2007 in Zambia) patients initiated onto stavudine or 
zidovudine now had tenofovir, if no signs of renal-insufficiency were detected, while 
those initiated onto tenofovir could substitute with stavudine, zidovudine, or abacavir 
[42–48]. 
All IeDEA sites obtained ethical approval from relevant local institutions before 
contributing anonymized patient data.  Approval for analysis of de-identified data was 
granted by Boston University’s Institutional Review Board.  
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Study design 
We performed a cohort analysis of data collected prospectively as part of routine 
care at clinics in the IeDEA multiregional collaboration. We included ART-naïve, HIV-
infected patients >16 years old initiating first-line ART between January 1 2005–
December 31 2012 for all countries except Nigeria, where patients initiating ART 
between January 1 2007–December 31 2012 were included as the roll out of ART started 
later. All patients had a minimum of 24 months of potential follow-up. Prior to April 
2010 national HIV treatment guidelines recommended the use of stavudine or zidovudine 
in first-line ART in all six included countries, thereafter, guidelines called for tenofovir 
or zidovudine to replace stavudine [42–46]. The only exception was in Zambia, which 
switched from stavudine or zidovudine to tenofovir in July 2007 [47, 48].  
 
Study variables 
All demographic (i.e. age, sex, clinic and country) and clinical (i.e. year of ART 
initiation, CD4 count, first-line NRTI (stavudine, zidovudine or tenofovir) and non-
nucleoside reverse transcriptase inhibitor (NNRTI)(nevirapine or efavirenz) 
characteristics measured at ART initiation came from routinely collected clinic data. 
Hemoglobin levels and weight at ART initiation were available for South Africa, Zambia, 
Kenya and Uganda, while WHO staging and tuberculosis status were only available for 
South Africa.  
The primary outcome variable was the proportion of patients who underwent a 
single-drug substitution in the first 24-months on ART. Follow-up time of 24-months was 
  
9 
chosen as monitoring and time to development of toxicity/side-effects differ between 
drugs. Laboratory monitoring for tenofovir and zidovudine is conducted early on after 
treatment initiation, while for stavudine monitoring begins more often when the patient 
begins to develop clinical symptoms of toxicity (up to 24–48 months on ART [49]) 
diagnosed at a medical visit [2,3]. Single-drug substitution was defined as substitution of 
the NRTI only within first-line ART. The reason for single-drug substitutions was not 
available. 
 
Statistical analysis 
Patient characteristics at ART initiation were summarized with descriptive 
statistics and stratified by country. To look for trends in the use of stavudine in first-line 
ART and SDSs over time, proportions of patients initiating stavudine or having a single-
drug substitution in the first 24 months on ART were stratified by country and year of 
ART initiation and plotted from January 1 2005–December 31 2012, separately, with 
Nigeria being the exception, as data begin in 2007. To test an additional hypothesis that 
tenofovir was being used among patients with contraindications to stavudine prior to 
guideline change, we looked at rates of single-drug substitutions by NRTI over time. 
Fine and Gray’s competing risks regression method [50] was used to identify if 
the choice of NRTI in first-line ART was a predictor of single-drug substitution in the 
first 24 months on ART, accounting for attrition as competing risks and adjusted for age, 
sex, year of ART initiation, CD4 count and first-line NNRTI depending on country, with 
robust estimates at site level. We ran two models for each country. In both, we included 
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all demographic and clinical characteristics at treatment initiation and year of ART 
initiation. The models differed as year of treatment initiation and NRTIs used are highly 
associated and therefore each model used only one of the two. Follow up time began at 
ART initiation and ended at the earliest of: 1) single-drug substitution; 2) initiation of 
second-line ART; 3) discontinuation of treatment 3) loss to follow-up (defined as not 
attending the clinic in the last 6 months); 4) death; 5) transfer; 6) completion of 24-
months of follow-up; or 7) or date of dataset closure(December 31 2014). 
We assessed interaction between gender and NRTI, CD4 count and NRTI and 
hemoglobin levels and NRTI on the additive scale by calculating the risk due to 
interdependence (R(I)) [51]. 
 
Bayesian analysis 
As prior studies have been conducted on the topic, we conducted a Bayesian 
analysis [52]. To do so, point estimates and corresponding 95% confidence intervals (CI) 
for priors were obtained from previous publications assessing predictors of SDS [30–38]. 
Ratio measures for each potential predictor of single drug-substitution (age, sex, clinic, 
CD4 count, weight, hemoglobin levels, WHO stage, tuberculosis, NRTI and NNRTI used 
in first-line regimen) were extracted from the existing literature. We performed a meta-
analysis using random effects models, due to heterogeneity in estimates, to first create 
weighted summary estimates for each individual predictor, separately, from the existing 
literature (i.e. the prior). We then used the same technique to calculate the summary 
estimates of each individual predictor, separately, from our data (i.e. the likelihood) and 
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then combined the prior and likelihood estimates for each predictor, separately, to 
calculate a combined summary estimate (i.e. the posterior) and corresponding Bayesian 
credible intervals (CrI).  
 
Sensitivity analysis 
As we may have unmeasured confounding due to missing variables (i.e. WHO 
stage, hemoglobin and weight) in our estimates from Zambia, East and West Africa we 
conducted a bias analysis [53].  
 
Multiple imputation 
Multiple imputation conducted in SAS was used to account for missingness [54]. 
Results shown are based on the observed data as results on imputed data showed similar 
results.  
 
RESULTS  
We included 377,656 patients in the analysis (Table 1), 24% initiated a stavudine-
based ART regimen, ranging from 25% in Zambia and Uganda to 60% in South Africa. 
Zambia contributed the largest number of patients (n=205,140) and Nigeria the smallest 
(n=7,434). Demographic and clinical characteristics were similar across countries. 
Patients were predominately female (62.9%) with a median age of 35.2 years 
(interquartile range (IQR):29.8–42.0) and a median time on treatment of 24.0 months 
(IQR:12.1–24.0), which did not differ by cohort. At ART initiation patients had a median 
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CD4 count of 155 cells/mm
3 
(IQR:74–241), with patients in South Africa having the 
lowest median (130 cells/mm
3
; IQR:58–199) and Nigeria the highest (192 
cells/mm
3
;IQR:91–312).  
When stratified by year, gender, weight and age remained unchanged over time, 
while patients’ cellular immunity at ART initiation improved in all countries. 
Additionally, the proportion of patients with tuberculosis and WHO III/IV stage declined 
over time in South Africa. Over 70% of patients in all countries remained alive and in 
care over 24 months on treatment. Overall attrition (combination of death and loss to 
follow-up) was 17.8% (95%CI:17.7–17.9%) and fairly consistent across countries with, 
Zambia having the lowest rate of attrition in the first 24 months on ART at 15.3% 
(95%CI:15.2–15.5%) and Nigeria the highest at 23.5% (95%CI:22.5–24.4%). 
 
Compliance with WHO guidelines: phasing out of stavudine in first-line ART 
All countries, with the exception of South Africa where, in 2009, 95% of patients 
still initiated stavudine, began phasing out stavudine prior to the WHO guidelines making 
the change in 2010 (Figure 1). Zambia, Kenya and Uganda, began replacing stavudine 
with zidovudine in first-line ART as early as 2007 (2005 in Zambia), potentially in 
parallel with the WHO’s recommendation for lower dose stavudine use (30mg instead of 
40mg [55]). Tenofovir was introduced after the WHO recommended its use in first-line 
therapy in 2010 (2007 in Zambia), as such, within two years of the change in 2012, fewer 
than 10% of patients were being initiated on stavudine. Prior to 2010 in Cote d’Ivoire and 
Nigeria, stavudine and zidovudine were used interchangeably, while stavudine use 
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decreased substantially, with less than 10% of patients initiating the drug after 2010, 
when both countries decided on zidovudine as the NRTI of choice in first-line ART. 
Tenofovir had yet to be introduced in first-line ART in Cote d’Ivoire or Nigeria before 
2012 due to cost [3]. 
 
Decrease in single-drug substitutions associated with the phase out of stavudine 
While the WHO policy change was accompanied by a clear shift away from 
stavudine to tenofovir, the impact on single drug substitutions is less clear. Overall, 
single-drug substitutions affected 8.8%(95%CI:8.7–8.9%) of patients in the first 24 
months on ART  with 38% of single-drug substitutions related  to stavudine compared to 
49% and 13% related to zidovudine or tenofovir, respectively. The decrease in single-
drug substitutions was associated with the phasing out of stavudine in first-line ART, 
decreasing from an overall rate of 11.3%(95%CI:11.2–11.4%) prior to 2010 when 55% 
of patients were initiating stavudine to 5.4%(95%CI:5.3–5.5%) after 2010 when only 
7.4% of patients initiated  treatment with this drug. However, it is important to note that 
in all countries single-drug substitutions began roughly two years prior to the WHO 
guideline change in 2010 (Figure 2). For all countries competing risks regression models 
adjusted for year confirmed our results, showing a decrease in the hazards of single-drug 
substitutions in accordance with the decrease in the use of stavudine (Table 4). 
 
Single-drug substitutions stratified by initiating NRTI and substitution NRTI  
In addition to the variation observed in relation to the policy change, we also 
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observed differences in rates of substitution by treatment regimen. Patients initiating 
stavudine (13.9%; 95%CI:13.7–14.1%) and zidovudine (12.0%; 95%CI:11.8–12.2%) had 
higher rates of single drug substitution compared to patients initiating tenofovir (2.8%; 
95%CI:2.7–2.9%). Also, while rates of substitution decreased over time for patients on 
tenofovir, they remained stable for zidovudine patients and increased for those on 
stavudine (Figure 3). All countries followed the national ART guidelines outlining the 
antiretroviral eligible for substitution. These included tenofovir, stavudine, zidovudine or 
abacavir depending on NRTIs included in the first-line regimen with the occasional use 
of didanosine as an alternative (Figure 4). Zidovudine was the most common single-drug 
substitution used for both tenofovir (50%; 95%CI:48.6–51.6%) and stavudine (67.9%; 
95%CI:67.2–68.6%), while stavudine was the single-drug substitution for a zidovudine-
based first-line regimen (65.1%; 95%CI:64.2–66.0%).  
Consistent with known toxicity patterns, single-drug substitutions occurred earlier 
for patients on zidovudine (median 8.1 months after treatment start; IQR:2.3–17.0) and 
tenofovir (median 10.2 months after treatment start; IQR:3.6–18.1) compared to 
stavudine (median 14.2 months; IQR:7.3–19.6) after treatment start.  
 
 Changing the NRTI used in first-line ART could explain the temporal trends in 
single-drug substitutions   
Adjusted competing risks regression models evaluating the association between 
choice of NRTI used in first-line ART and single-drug substitutions helped us to confirm 
that the decrease in rates of SDSs was associated with the phasing out of stavudine for 
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tenofovir or zidovudine in first-line ART. Adjusted models showed that patients initiating 
tenofovir in Southern and East Africa were 2 0% to 95% less likely to undergo a 
substitution than patients initiating stavudine (Table 2). Posterior Bayesian estimates 
using an informative prior, showed close to an 80% reduction in the risk of single-drug 
substitution s(posterior risk ratio (RR):0.21; 95% credible interval (CrI):0.20–0.22) when 
comparing tenofovir to stavudine (Table 3). With the exception of Zambia, where we saw 
an increase in the hazards of single-drug substitution when comparing zidovudine to 
stavudine (hazard ratio (HR):2.59; 95%CI:2.3–3.0) and Kenya, where we saw no 
association (HR:1.13; 95%CI:0.99–1.28)(Table 2), patients on zidovudine compared to 
stavudine in Uganda, Cote d’Ivoire and Nigeria had a 75% to 85% decrease in the 
hazards of single-drug substitutions when compared to stavudine.  Posterior Bayesian 
estimates using an informative prior, showed close to a 70% reduction in the risk of 
single-drug substitutions (posterior RR:0.31; 95%CrI:0.30–0.33)(Table 3).  
Our results also suggest that females compared to males have a 50% increase in 
the risk of single-drug substitution (posterior RR:1.48; 95%CrI:1.43–1.52)(Table 2 and 
Table 3). Since we believed changes in the trends of substitutions for sex could vary by 
NRTI used in first-line ART we calculated the risk due to interdependence (R(I)). With 
the exception of Zambia and Kenya, where the R(I) was essentially zero, in the other four 
countries showed a positive interdependence (Uganda 2%; Cote d’Ivoire 4%, South 
Africa 5% and Nigeria 6%). In other words, in Nigeria for example, 6% of single-drug 
substitutions in women on stavudine is related to the dual action of female gender and 
stavudine. The risk of single-drug substitutions in the doubly exposed (females exposed 
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to stavudine) was 41.9% vs. the risk of 6.0% in the doubly unexposed (males unexposed 
to stavudine). We did not see any signs of interaction when assessing CD4 count and 
NRTI and hemoglobin levels and NRTI.  
 
Bias Analysis 
Bias analyses simulating a confounder that would overestimate the effect of 
tenofovir or zidovudine vs. stavudine showed that in order for adjustment for an 
unmeasured confounder to bring our results close to null, the confounder would have to 
be present in <20% in those exposed to tenofovir or zidovudine, extremely common 
among patients exposed to stavudine (65%) and be a very strong predictor of single-drug 
substitution (RR >11), highly unlikely as shown in the example of Cote d’Ivoire in Table 
5. When assessing the situation in Zambia where we were interested in a confounder that 
would underestimate the effect of zidovudine vs. stavudine on single-drug substitutions, 
the confounder would have to be present in at least 70% in those exposed to zidovudine, 
less common (15%) in patients exposed to stavudine and be a very strong predictor of 
single-drug substitutions (RR >10) in order to get a null effect, also highly unlikely 
(Table 6). 
 
DISCUSSION 
In the largest study to date, across multiple countries on the African continent, we 
show steady decrease in single-drug substitutions corresponding to the phasing out of 
stavudine, in accordance with the WHO guidelines, from an overall rate of 11% prior to 
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2010 when 55% of patients were initiating stavudine to 5% after 2010 when only 7% of 
patients initiated treatment with this drug. Using Bayesian methods [31], although high 
heterogeneity between studies for the majority of estimates, we were able to estimate an 
80% decrease in the risk of single-drug substitutions when comparing tenofovir to 
stavudine, and over 70% decrease when comparing stavudine to zidovudine, further 
highlighting the better safety profile associated with tenofovir and zidovudine compared 
to stavudine. Our results also showed a decrease in the rates of single-drug substitutions 
from 2005 to 2012 for patients on tenofovir, providing evidence to support the notion that 
patients in earlier years where being initiated on tenofovir due to contraindications to 
stavudine or zidovudine and therefore at higher risk of toxicity/side-effects.  
Time to substitution varied depending on the NRTI used in first-line ART, with 
zidovudine and tenofovir occurring early after treatment initiation and at a higher rate 
later on in follow-up amongst patients on stavudine. This is consistent with previous 
studies conducted in sub-Saharan Africa [30–38], however, it is important to note that 
time to substitution is partly a function of the frequency of monitoring, which differs for 
each NRTI. Laboratory monitoring for tenofovir and zidovudine is often conducted early 
on after treatment initiation, while for stavudine monitoring begins more often when the 
patient begins to develop clinical symptoms of toxicity diagnosed at a medical visit [2,3].  
Females, compared to males, had a 50% increase in the risk of SDS in our study, 
consistent with previous research [30,32–37]. By assessing effect measure modification 
on the additive scale, we also showed that depending on country, 2% to 6%, of single-
drug substitutions in women on stavudine was related to the dual action of female gender 
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and stavudine. Although we could not confirm the reason for substitution in our study, 
previous research has reported women on stavudine are at higher risk of toxicity/side-
effects than men [49, 56, 57] and that differences in risk of toxicity observed between 
genders could be related to differences in susceptibility or to a higher level of adherence 
to therapy achieved by women [49]. 
In addition to the size of our study population, we are the first to evaluate trends 
in single-drug substitutions over almost a decade of treatment in public sector since the 
roll out of ART in 2004 in six countries in sub-Saharan Africa.  However, our findings 
should be considered in light of the study limitations. First, this study mostly represents 
patients from urban areas. Although some clinics are run out of tertiary hospitals, the 
majority operate at the primary care level, are led by nurses or clinical officers rather than 
physicians and are part of the public health care system of the country and may, 
therefore, not be generalizable to other clinics. Second, due to the lack of documentation 
of reasons for single-drug substitutions for almost 95% of events amongst patients with 
the event, we are likely underestimating the frequency and type of side effects due to less 
than perfect surveillance. There is a chance single-drug substitutions in our study were 
driven by the policy change and not by side-effects/toxicity of stavudine. When we 
conducted a similar study in our pediatric population we did see a substantial spike in 
single-drug substitutions around the time of the guideline change as clinicians were 
substituting stavudine, regardless if the patient was tolerating stavudine well, with 
zidovudine or tenofovir. If substitutions were being driven by the guidelines in adults we 
believe we would see a similar increase, which is not present in these data. Third, it is 
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possible that our populations differed with respect to some unmeasured confounder, as 
data on WHO staging and tuberculosis at ART initiation were only available for South 
Africa and often poorly recorded, while hemoglobin levels and weight at ART initiation 
were not available for West Africa countries. We may therefore have residual 
confounding in our estimates from those countries. However, our bias analysis suggests 
such an unmeasured confounder would be extremely unlikely in our cohort. Fourth, 
multiple imputation helps make it possible to handle missing data routinely and improve 
the validity of research. However, deviations from the assumptions needed [54] could 
have led to unpredictable biases in our parameter estimates. Finally, data on WHO 
staging and tuberculosis at ART initiation were only available for South Africa and often 
poorly recorded, while hemoglobin levels and weight at ART initiation were not 
available for West Africa countries, as such we may have residual confounding in our 
estimates from those countries. 
  
 
2
0
 
Table 1. Clinical and demographic characteristics at initiation of antiretroviral therapy and outcomes over 24-months of follow-up amongst adults initiated on treatment 
stratified by country (N=377,656), 2005–2012 
 Country 
Characteristics 
South Africa 
(n=47290) 
n (%) 
Zambia 
(n=205140) 
n (%) 
Kenya 
(n=73547) 
n (%) 
Uganda 
(n=31645) 
n (%) 
Cote d’Ivoire 
(n=12600) 
n (%) 
Nigeria 
(n=7434) 
n (%) 
Total 
(N=377656) 
n (%) 
Nucleoside Reverse Transcriptase Inhibitor 
 stavudine 28698 (60.7) 51289 (25.0) 36399 (49.5) 7846 (24.8) 7011 (55.6) 2775 (37.3) 87456 (23.2) 
 tenofovir 18592 (39.3) 115108 (56.1) 17686 (24.1) 4796 (15.2) - - 156182 (41.4) 
 zidovudine - 38743 (18.9) 19462 (26.5) 19003 (60.1) 5589 (44.4) 4659 (62.7) 134018 (35.5) 
Non-nucleoside Reverse Transcriptase Inhibitor at First-line ART Initiation  
 efavirenz 38563 (81.6) 88873 (43.3) 22835 (31.1) 10486 (33.1) 5129 (40.7) 717 (9.6) 166603 (44.1) 
 nevirapine  8727 (18.5) 116267 (56.7) 50712 (69.0) 21159 (66.9) 7471 (59.3) 6717 (90.4) 211053 (55.9) 
Gender         
 male 17660 (37.3) 78965 (38.5) 25304 (34.4) 11598 (36.7) 4337 (34.4) 2354 (31.7) 140218 (37.1) 
 female 29630 (62.7) 126175 (61.5) 48243 (65.6) 20047 (63.4) 8263 (65.6) 5080 (68.3) 237438 (62.9) 
Age (years) 
 18–24.9 2842 (6.0) 18905 (9.2) 6868 (9.3) 3094 (9.8) 637 (5.1) 483 (6.5) 32829 (8.7) 
 25–29.9 8213 (17.4) 36398 (17.7) 11257 (15.3) 5708 (18.0) 1724 (13.7) 1423 (17.1) 64723 (17.1) 
 30–39.9 21005 (44.4) 89589 (43.7) 28534 (38.8) 13529 (42.8) 5406 (42.9) 3017 (40.6) 161080 (42.7) 
 40–49.9 10948 (23.2) 42571 (20.8) 17943 (24.4) 6940 (21.9) 3475 (27.6) 1644 (22.1) 83521 (22.1) 
 >50 4282 (9.1) 17677 (8.6) 8945 (12.2) 2374 (7.5) 1358 (10.8) 867 (11.7) 35503 (9.4) 
 median (IQR) 35.0 (30.0–42.0) 34.9 (29.5–41.4) 36.2 (30.1–43.8) 34.9 (29.3–41.1) 37.2 (31.5–43.7) 35.4 (29.9–43.0) 35.2 (29.8–42.0) 
CD4 count (cells/mm
3
) 
 0–49  8734 (18.5) 10533 (5.1) 12205 (16.6) 5286 (16.7) 1923 (15.3) 850 (11.4) 151617 (40.2) 
 50–99  7082 (15.0) 12070 (5.9 ) 9720 (13.2) 3743 (11.8) 1290 (10.2) 733 (9.9) 39531 (10.5) 
 100–199  14097 (29.8) 25615 (12.5) 19523 (26.5) 8558 (27.0) 2756 (21.9) 1457 (19.6) 34638 (9.2) 
 >200  9955 (21.1) 30204 (14.7) 23609 (32.1) 9396 (29.7) 3859 (30.63) 2841 (38.2) 72006 (19.1) 
 missing 7422 (15.7) 126718 (61.8) 8490 (11.5) 4662 (14.7) 2772 (22.0) 1553 (20.9) 79864 (21.2) 
 median (IQR) 130 (58–199) 165 (87–255) 155 (70–252) 156 (69–230) 163 (70–253) 192 (91–312) 155 (74–241) 
Hemoglobin (ug/dL) 
 >10 19930 (42.1) 19300 (9.4) 36382 (49.5) 14363 (45.4) - - 89975 (23.8) 
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 Country 
Characteristics 
South Africa 
(n=47290) 
n (%) 
Zambia 
(n=205140) 
n (%) 
Kenya 
(n=73547) 
n (%) 
Uganda 
(n=31645) 
n (%) 
Cote d’Ivoire 
(n=12600) 
n (%) 
Nigeria 
(n=7434) 
n (%) 
Total 
(N=377656) 
n (%) 
 <10 6152 (13.0) 9117 (4.4) 15689 (21.3) 3337 (10.6) - - 34295 (9.1) 
 missing 21208 (44.9) 176723 (86.2) 21476 (29.2) 13945 (44.1) - - 233352 (65.3) 
 median (IQR) 11.6 (10.0–13.0) 10.9 (9.4–12.2) 11.2 (9.6–12.8) 11.9 (10.5–13.3) - - 11.3 (9.8–12.8) 
Weight (kg) median (IQR) 61.9 (54.2–71.0) 54.1 (48.0–61.0) 55.0 (49.0–62.0) 54.0 (48.0–61.0) - - 55.0 (49.0–62.4) 
World Health Organization Stage  
 I/II 21965 (46.5) - - - - - 21965 (46.5) 
 III/IV 24980 (52.8) - - - - - 24980 (52.8) 
 missing 345 (0.7) - - - - - 345 (0.7) 
Time (months) median (IQR) 24.0(12.3–24.0) 24.0 (12.9–24.0) 24.0 (10.0–24.0) 24.0 (12.8–24.0) 24.0 (11.8–24.0) 24.0 (8.7–24.0) 24.0 (12.1–24.0) 
Vital status over 24-months of follow-up 
        Death n (%) 3928 (8.3) 12611 (6.2) 5121 (7.0) 1674 (5.3) 660 (5.2) 119 (1.6) 24113 (6.4) 
        Loss  n (%) 5863 (12.4) 18859 (9.2) 10768 (14.6) 3761 (11.9) 2308 (18.3) 1626 (21.9) 1626 (21.9) 
        Attrition n (%) 9791 (20.7) 31470 (15.3) 15889 (21.6) 5435 (17.2) 2968 (23.6) 1745 (23.5) 67298 (17.8) 
        Transfers n (%) 3757 (7.9) 31271 (15.2) 2563 (3.5) 2618 (8.3) 285 (2.3) 30 (0.4) 40524 (10.7) 
        Alive n (%) 33742 (71.4) 142399 (69.4) 55095 (74.9) 23592 (74.6) 9347 (74.2) 5659 (76.1) 269834 (71.4) 
Primary outcome over 24-months of follow-up 
      Single-drug 
substitution 
n (%) 5686 (12.0) 13574 (6.6) 8074 (11.0) 2654 (8.4) 1512 (12.0) 1695 (22.8) 33441 (8.85) 
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Figure 1. Trends in the stavudine use in first-line antiretroviral therapy for treatment naïve 
patients stratified by country and year since ART guidelines changed (N=377,656) 
*Dashed lines represents the change in national guidelines to introduce zidovudine or tenofovir 
into first-line ART (2007 for Zambia and 2010 for all other countries) 
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Figure 2. Proportion of single-drug substitutions over the first 24-months on antiretroviral 
therapy stratified by year of since ART guidelines changed for all countries (N=377,656) 
 
*Dashed lines represents the change in national guidelines to introduce zidovudine or tenofovir 
into first-line ART (2007 for Zambia and 2010 for all other countries) 
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Table 2. Competing risks regression models examining predictors of single-drug substitution over 24-months on ART in all countries (N=377,656) 
  Single-Drug Substitution 
  Southern Africa East Africa West Africa 
Variable measured 
at ART initiation 
SOUTH AFRICA 
Adjust Hazards 
Ratio (95% CI) 
ZAMBIA 
Adjust Hazards 
Ratio (95% CI) 
KENYA 
Adjust Hazards 
Ratio (95% CI) 
UGANDA 
Adjust Hazards 
Ratio (95% CI) 
COTE D’IVOIRE 
Adjust Hazards 
Ratio (95% CI) 
NIGERIA  
Adjust Hazards 
Ratio (95% CI) 
NRTI in first-line ART regimen    
 stavudine Reference Reference Reference Reference Reference Reference 
 tenofovir 0.13 (0.11–0.15) 0.80 (0.64–0.99) 0.47 (0.44–0.50) 0.05 (0.02–0.11) - - 
 zidovudine - 2.59 (2.25–2.99) 1.13 (0.99–1.28) 0.13 (0.08–0.19) 0.24 (0.17–0.34) 0.14 (0.11–0.20) 
        NNRTI in first-line ART regimen    
 efavirenz Reference Reference Reference Reference Reference Reference 
 nevirapine 0.80 (0.69–0.92) 1.32 (1.11–1.58) 1.23 (0.97–1.55) 1.03 (0.67–1.59) 0.50 (0.35–0.72) 2.20 (1.52–3.20) 
Sex        
 Male Reference Reference Reference Reference Reference Reference 
 Female   1.86 (1.70–2.03) 1.34 (1.21–1.50) 1.31 (1.25–1.38) 1.12 (0.93–1.34) 1.36 (1.15–1.61) 1.10 (0.97–1.26) 
Age (years)       
 16–24.9 0.63 (0.49–0.82) 0.82 (0.68–0.99) 0.85 (0.74–0.97) 1.04 (0.74–1.44) 0.63 (0.45–0.87) 1.04 (0.91–1.20) 
 25–29.9 0.83 (0.73–0.95) 0.87 (0.76–1.00) 0.85 (0.73–0.99) 0.95 (0.90–1.01) 0.88 (0.67–1.14) 0.88 (0.75–1.03) 
 30–39.9 Reference Reference Reference Reference Reference Reference 
 40–49.9 1.26 (1.15–1.39) 1.15 (1.02–1.30) 1.26 (1.15–1.37) 1.05 (0.98–1.14) 1.19 (1.08–1.31) 0.91 (0.88–0.95) 
 >50 1.45 (1.29–1.64) 1.13 (0.94–1.35) 1.56 (1.40–1.73) 0.97 (0.87–1.09) 1.33 (1.10–1.62) 0.84 (0.76–0.94) 
CD4 count (cells/mm
3
)      
>200 Reference Reference Reference Reference Reference Reference 
100–199 0.95 (0.85–1.06) 0.93 (0.83–1.05) 0.92 (0.83–1.01) 0.85 (0.63–1.14) 0.85 (0.72–1.00) 0.99 (0.88–1.11) 
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  Single-Drug Substitution 
  Southern Africa East Africa West Africa 
Variable measured 
at ART initiation 
SOUTH AFRICA 
Adjust Hazards 
Ratio (95% CI) 
ZAMBIA 
Adjust Hazards 
Ratio (95% CI) 
KENYA 
Adjust Hazards 
Ratio (95% CI) 
UGANDA 
Adjust Hazards 
Ratio (95% CI) 
COTE D’IVOIRE 
Adjust Hazards 
Ratio (95% CI) 
NIGERIA  
Adjust Hazards 
Ratio (95% CI) 
50–99 0.95 (0.84–1.09) 0.89 (0.77–1.02) 0.88 (0.76–1.00) 0.70 (0.49–1.01) 0.78 (0.75–1.06) 0.89 (0.64–1.23) 
<50 0.81 (0.72–0.92) 0.82 (0.67–1.00) 0.81 (0.71–0.92) 0.59 (0.42–0.85) 0.76 (0.66–0.90) 0.71 (0.56–0.90) 
Weight (kg) 1.02 (1.01–1.03) 1.00 (0.99–1.01) 1.01 (1.00–1.02) 1.00 (0.99–1.01) - - 
Hemoglobin (ug/dL)      
 >10 Reference Reference Reference Reference - - 
 <10 0.87 (0.79–0.97) 1.96 (1.73–2.22) 1.06 (1.03–1.10) 1.04 (0.76–1.42) - - 
WHO stage       
I/II Reference - - - - - 
III/IV 1.04 (0.95–1.15) - - - - - 
Tuberculosis       
No Reference - - - - - 
Yes 1.17 (1.04–1.32) - - - - - 
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 Table 3. Bayesian analysis: prior, likelihood and posterior estimates for predictors of single-drug substitution 
 Bayesian Estimates 
Variable 
Prior 
Risk Ratio 
(95% CI) 
Prior 
 I
2
, p-value 
Likelihood 
Risk Ratio 
(95% CI) 
Likelihood 
 I
2
, p-value 
Posterior 
Risk Ratio 
(95% CrI*) 
Posterior 
 I
2
, p-value 
NRTI       
 stavudine Reference  Reference  Reference  
 tenofovir 0.18 (0.15–0.20) 93.1%, p=0.000 0.22 (0.20–0.23) 99.3%, p=0.000 0.21 (0.20–0.22) 86.2%, p=0.007 
 zidovudine 0.41 (0.37–0.45) 97.1%, p=0.000 0.21 (0.18–0.25) 98.8%, p=0.000 0.31 (0.30–0.33) 96.4%, p=0.000 
NNRTI       
 efavirenz Reference  Reference  Reference  
 nevirapine 0.87 (0.74–1.01) 0.0%, p=0.521 0.86 (0.78–0.95) 89.3%, p=0.000 0.86 (0.79–0.93) 0.0%, p=0.902 
Sex       
 Male Reference  Reference  Reference  
 Female   1.76 (1.69–1.83) 96.9%, p=0.000 1.33 (1.28–1.38) 90.7%, p=0.000 1.48 (1.43–1.52) 99.0%, p=0.000 
Age (years)       
 16–24.9 0.96 (0.80–1.12) 0.0%, p=0.797 0.83 (0.77–0.90) 73.2%, p=0.002 0.85 (0.79–0.91) 54.1%, p=0.140 
 25–29.9 0.96 (0.80–1.12) 0.0%, p=0.797 0.91 (0.87–0.95) 9.5%, p=0.355 0.91 (0.87–0.95) 0.0%, p=0.552 
 30–39.9 Reference  Reference  Reference  
 40–49.9 0.91 (0.75, 1.07) 0.0%, p=0.971 1.00 (0.97–1.02) 93.8%, p=0.000 1.00 (0.97–1.02) 15.7%, p=0.276 
 >50 0.92 (0.76–1.08) 0.0%, p=0.741 1.07 (1.01–1.12) 94.1%, p=0.000 1.05 (1.00–1.11) 66.9%, p=0.082 
CD4 count (cells/mm
3
)       
>200 Reference  Reference  Reference  
100–199 0.93 (0.82–1.03) 0.0%, p=0.633 0.93 (0.88–0.98) 0.0%, p=0.721 0.93 (0.88–0.98) 0.0%, p=1.000 
50–99 0.93 (0.82–1.05) 0.0%, p=0.688 0.87 (0.81–0.94) 0.0%, p=0.462 0.88 (0.83–0.94) 0.0%, p=0.373 
<50 0.97 (0.85–1.09) 31.6%, p=0.223 0.78 (0.72–0.83) 0.0%, p=0.462 0.81 (0.76–0.86) 87.4%, p=0.005 
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 Bayesian Estimates 
Variable 
Prior 
Risk Ratio 
(95% CI) 
Prior 
 I
2
, p-value 
Likelihood 
Risk Ratio 
(95% CI) 
Likelihood 
 I
2
, p-value 
Posterior 
Risk Ratio 
(95% CrI*) 
Posterior 
 I
2
, p-value 
Weight (kg)** 1.00 (0.50–1.50) - 1.01 (1.00–1.01) 71.6%, p=0.014 1.01 (1.00–1.01) 0.0%, p=0.969 
Hemoglobin (ug/dL)       
 >10 Reference  Reference  Reference  
 <10 0.98 (0.96–1.01) 51.3%, p=0.152 1.05 (1.02–1.08) 95.6%, p=0.000 1.01 (0.99–1.03) 91.9%, p=0.000 
WHO stage       
I/II Reference  Reference  Reference  
III/IV 1.08 (1.0–1.16) 27.0%, p=0.241 1.04 (0.95–1.15) - 1.06 (1.00, 1.13) 0.0%, p=0.540 
Tuberculosis       
No Reference  Reference  Reference  
Yes 0.90 (0.71–1.13) - 1.17 (1.04–1.32) - 1.09 (0.97–1.20) 77.3%, p=0.036 
*CrI, Credible Interval (Bayesian) 
**Only posterior estimate that was estimated with a flat prior (RR=1.0; 95% CI: 0.5–1.5) 
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Table 4. Adjusted competing risk regression models examining year of ART initiation as a predictor of single-drug substitution 
over 24 months on ART in all countries (N=377,656) 
 
SOUTH AFRICA 
Adjust Hazards
¥
 
Ratio (95% CI) 
ZAMBIA 
Adjust Hazards
β
 
Ratio (95% CI) 
KENYA 
Adjust Hazards
β
 
Ratio (95% CI) 
UGANDA 
Adjust Hazards
β
 
Ratio (95% CI) 
COTE 
D’IVOIRE 
Adjust Hazards
€
 
Ratio (95% CI) 
NIGERIA 
Adjust Hazards
€
 
Ratio (95% CI) 
Year initiated onto ART 
2005 3.76 (3.24–4.36) 4.52 (2.72–7.52) 0.71 (0.62–0.82) 1.01 (0.29–3.55) 2.30 (1.55–3.42) - 
2006 4.14 (3.55–4.84) 4.51 (2.75–7.39) 1.31 (1.16–1.49) 2.72 (1.64–4.49) 1.93 (0.93–3.99) - 
2007 4.38 (3.83–5.01) 4.93 (2.97–8.18) 1.66 (1.60–1.73) 5.07 (3.08–8.33) 4.67 (3.20–6.82) 3.76 (2.20–3.45) 
2008 4.08 (2.91–5.73) 4.44 (2.72–7.25) 1.76 (1.34–2.31) 1.28 (0.66–2.50) 9.85 (7.49–13.0) 3.87 (2.42–6.19) 
2009 5.51 (4.36–6.97) 3.53 (2.00–6.21) 1.85 (1.60–2.14) 1.67 (0.94–2.95) 7.10 (5.85–8.62) 4.15 (2.76–6.23) 
2010 2.49 (1.73–3.56) 3.52 (1.86–6.64) 1.87 (1.75–2.02) 2.30 (0.76–6.92) 4.09 (2.73–6.11) 3.98 (3.17–5.00) 
2011 0.96 (0.85–1.08) 1.97 (0.93–4.15) 1.23 (1.21–1.24) 0.88 (0.64–1.21) 2.56 (1.56–4.21) 0.96 (0.50–1.83) 
2012 Reference Reference Reference Reference Reference Reference 
¥
Models also adjusted for age, non-nucleoside reverse transcriptase inhibitor, WHO stage, hemoglobin levels, CD4 count, gender and 
tuberculosis status at ART initiation 
β
Models also adjusted for age, non-nucleoside reverse transcriptase inhibitor, hemoglobin levels, CD4 count and gender at ART initiation 
€
Models also adjusted for age, non-nucleoside reverse transcriptase inhibitor, CD4 count and gender at ART initiation 
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Figure 3. Rates of single-drug substitution by year and NRTI used in first-line ART 
(n=33,441) 
*Dashed lines represents the change in national guidelines to introduce zidovudine or tenofovir 
into first-line ART (2007 for Zambia and 2010 for all other countries) 
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Figure 4. Proportion of patients with a single-drug substitution stratified by initiating NRTI and substituting NRTI in sub-
Saharan Africa (n=33,441) 
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Table 5. Estimates of the effect of zidovudine versus stavudine group on single-drug substitution in Cote D’Ivoire, corrected for an 
unmeasured confounder for various estimates of the prevalence of the confounder and the effect of the confounder on single-drug 
substitution. 
 
Prevalence in 
  
 
RR (Confounder-single-drug substitution) 
 
zidovudine 
group 
stavudine 
group 10 10.25 10.5 10.8 11 11.3 11.5 11.75 12 12.25 12.5 
0.20 0.65 0.96 0.97 0.97 0.98 0.98 0.99 0.99 1.00 1.00 1.01 1.01 
0.25 0.50 0.67 0.67 0.67 0.67 0.68 0.68 0.68 0.68 0.68 0.68 0.69 
0.30 0.55 0.63 0.63 0.64 0.64 0.64 0.64 0.64 0.64 0.65 0.65 0.65 
0.35 0.60 0.61 0.61 0.61 0.61 0.61 0.61 0.61 0.62 0.62 0.62 0.62 
0.40 0.65 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.60 0.60 
0.45 0.70 0.57 0.57 0.57 0.57 0.57 0.57 0.57 0.58 0.58 0.58 0.58 
0.50 0.75 0.55 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56 
0.55 0.80 0.54 0.54 0.54 0.54 0.55 0.55 0.55 0.55 0.55 0.55 0.55 
0.60 0.85 0.53 0.53 0.53 0.53 0.53 0.53 0.54 0.54 0.54 0.54 0.54 
0.65 0.90 0.52 0.52 0.52 0.52 0.53 0.53 0.53 0.53 0.53 0.53 0.53 
0.70 0.95 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 
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Table 6. Estimates of the effect of zidovudine versus stavudine group on single-drug substitution in Zambia, corrected for an 
unmeasured confounder for various estimates of the prevalence of the confounder and the effect of the confounder on single-drug 
substitution. 
Prevalence in 
  
 
RR (Confounder-single-drug substitution) 
 
zidovudine 
group 
stavudine 
group   10 10.25   10.5 10.8 11 11.3 11.5 11.75 12 12.25 12.5 
0.7 0.15 1.04   1.03 1.03 1.02 1.01 1.01 1.00 0.99 0.99 0.98 0.98 
0.71 0.2 1.23 1.22 1.21 1.21 1.20 1.19 1.19 1.18 1.18 1.17 1.17 
0.72 0.25 1.41 1.40 1.39 1.39 1.38 1.38 1.37 1.37 1.36 1.36 1.35 
0.73 0.3 1.58 1.58 1.57 1.57 1.56 1.56 1.55 1.55 1.54 1.54 1.53 
0.74 0.35 1.75 1.75 1.74 1.74 1.73 1.73 1.73 1.72 1.72 1.71 1.71 
0.75 0.4 1.92 1.92 1.91 1.91 1.90 1.90 1.90 1.89 1.89 1.89 1.88 
0.76 0.45 2.09 2.08 2.08 2.07 2.07 2.07 2.06 2.06 2.06 2.06 2.05 
0.77 0.5 2.25 2.24 2.24 2.24 2.23 2.23 2.23 2.23 2.22 2.22 2.22 
0.78 0.55 2.40 2.40 2.40 2.39 2.39 2.39 2.39 2.39 2.38 2.38 2.38 
0.79 0.6 2.56 2.55 2.55 2.55 2.55 2.55 2.54 2.54 2.54 2.54 2.54 
0.8 0.75 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 3.06 
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CHAPTER THREE 
 
Adverse reactions to treatment are a major cause of non-adherence to ART and 
poor retention in care [58–60]. It was expected that initiating patients on tenofovir would 
lead to improved adherence and reduced lost to follow-up [3], with implications for 
longer-term health outcomes [61]. However, the impact of initiating patients on tenofovir 
as standard of care on patient outcomes has only been evaluated in observational studies. 
These studies have consistently reported a protective association between tenofovir use 
and single-drug substitution [30–38], a widely used marker for adverse reactions to 
treatment. Yet many of these same observational studies have reported mixed results for 
the association between initiating tenofovir and death, loss, and immunologic or viral 
load response [30–34]. These studies were performed at single sites and typically well-
resourced clinics, limiting generalizability [30–34].  
The studies conducted prior to the change in the guidelines [30, 31] focused 
mainly on effects of tenofovir in the subpopulation of patients receiving tenofovir due to 
contraindications to stavudine and/or zidovudine and may not be informative of treatment 
effects for the larger population of patients initiating tenofovir as standard of care after 
the guideline changes. Finally, and most importantly, prior studies used methods which 
may be vulnerable to confounding by indication; e.g., pancreatitis, kidney disease and 
obesity are contraindications to stavudine, but are also associated with poor treatment 
outcomes [62]. As a result, comparisons between patients initiating tenofovir versus not 
in the existing literature may be biased. To assess the impact of tenofovir in first-line 
ART on patient outcomes, we evaluated the effect of national guideline changes in South 
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Africa (SA) and Zambia using a quasi-experimental regression discontinuity design.  
 
METHODS 
Data source 
Data were obtained from the International epidemiological Databases to Evaluate 
AIDS in Southern Africa (IeDEA-SA, www.iedea-sa.org), a collaboration of HIV 
treatment cohorts in Southern Africa [41]. We included cohorts from the Gugulethu, 
Hlabisa, Khayelitsha, Themba Lethu ART programs, and Tygerberg Hospital in SA and 
the Centre for Infectious Disease Research cohort in Zambia. Some IeDEA clinics from 
SA and Zambia stopped reporting to IeDEA shortly after the guideline changes and were 
excluded from the analysis. 
All IeDEA-SA sites obtained ethical approval from relevant local institutions. 
Boston University’s Institutional Review Board granted approval of secondary analyses 
of de-identified data. 
 
Study design 
We conducted a prospective cohort study using a regression discontinuity design 
including ART-naïve, non-pregnant, tuberculosis free, HIV-infected patients >16 years 
initiating first-line ART. Patients were included in the analysis if they initiated ART 
within the period +/-12 months of guideline changes. Guideline changes occurred on 
April 1 2010 in SA [42] and July 1 2007 in Zambia [47, 48]. Some facility-level variation 
occurred when the guidelines were rolled out in Zambia (all +/- 3 months of July 1 2007), 
as such we used facility-specific implementation dates in our analysis of the Zambian 
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data to assign patients to the guidelines that were in effect on the date they initiated ART. 
All patients had the potential for at least 24 months of follow-up after date of initiation. 
 
Outcomes  
Our primary outcomes were death, attrition (combined death and loss), single-
drug substitution, immunological response and viral load failure, all evaluated over 24 
months. Mortality in SA was ascertained via family or hospital report, active tracing, 
and/or linkage with the SA National death registry [63, 63]. Zambia does not have a 
death registry; mortality was ascertained via family or hospital report or via active 
tracing. Mortality estimates were not weighted to account for rates of death amongst 
those lost to follow-up. Loss was defined as having not attended a clinic visit within 6-
months prior to the closure date of each program. Single-drug substitution was defined as 
only changing the nucleoside reverse transcriptase inhibitor (NRTI) within first-line 
ART, which was standard of care in both countries for patients experiencing an adverse 
reaction to the initially-prescribed NRTI [42, 47, 48]. Patients that switched to second-
line ART were censored at start of second-line. Viral load failure was defined as two 
consecutive viral loads, at least two weeks apart, >400 copies/mL [42, 47] and was 
evaluated in SA only as treatment monitoring in Zambia used CD4 counts only during the 
period of study [47]. The first elevated viral load measurement had to fall in the first 18 
months on ART with a window +/- 6 months, with documentation of the second viral 
load measurement confirming failure within 24 months (+/- 6 months) for those alive and 
in care.  The first elevated viral load was considered the date of failure. CD4 response 
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was calculated as mean change in CD4 count from ART initiation to 24-months on 
treatment. We used the first value in the 6-month window around 24 months of follow-up 
for those alive and in care. To assess long term outcomes, we analyzed death, attrition, 
single-drug substitution and immune response over 48 months in Zambia; there was 
insufficient follow-up time to assess outcomes beyond 24-months in SA.  
 
Statistical analysis 
Regression discontinuity design [64–72] was used to compare patients initiating 
just before and after guidelines changes. So long as dates of ART initiation are not 
manipulated to gain access to tenofovir — e.g. a provider delaying ART initiation for 
patients because they know tenofovir will soon become available — the guideline change 
offers a natural experiment to evaluate the impact of tenofovir as standard of care on 
patient outcomes. In contrast to a simple pre/post analysis, which can be confounded by 
secular trends, we focused our comparison on patients initiating immediately before and 
after the date of the guideline change. Since the precise date when a patient initiates ART 
is a product of random factors related to the decision to seek care, weather and transport 
conditions, arrival of laboratory results, and clinic congestion (among others), patients 
initiating ART just before vs. just after the guideline change are expected to be similar on 
both observed and unobserved covariates, as in randomized trials. Also, even though 
there may be subtle changes that vary over time, specifically at the level of the clinic, we 
are assuming that everything else is held constant.  
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Intention-to-treat (ITT) effects were estimated separately for each country and 
each outcome on a risk difference scale using local linear regression models with 
heteroskedasticity-robust standard errors.  We controlled for continuous linear trends 
over time in outcomes with respect to date of initiation, allowing for separate slopes 
before and after guideline change. We overlaid scatter plots binned in weekly intervals 
displaying the average outcomes in each bin. Our treatment effect was estimated as the 
intercept shift on the date of the guideline change. A data-driven optimal bandwidth was 
calculated for each outcome using the Imbens and Kalyanaraman bandwidth selector 
[73]. Due to imprecision in the implementation of the guidelines, we excluded patients 
initiating +/- 14 days of the guideline change in our primary estimates, but included them 
in sensitivity analyses (Figure 6). We also estimated combined models, with interaction 
terms between country and all model parameters, increasing precision by pooling data 
from SA and Zambia. 
To assess comparability of patients initiating just before and after guideline 
change, we assessed differences in observed baseline clinical and demographic 
characteristics using regression models similar to the ITT, where instead of regressing the 
outcome on the model parameters we regressed each baseline observable separately [69]. 
As with a baseline table in a randomized trial, similarity in observed characteristics 
generates confidence that treatment was (quasi-)randomly assigned for patients initiating 
ART close to the date of the guideline change. Additionally, to assess whether dates of 
initiation were systematically manipulated, we plotted a histogram of initiation dates and 
analyzed the distribution for evidence of bunching on one side of the threshold [74, 75].  
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RESULTS 
A total of 16,179 patients in SA and 36,115 in Zambia were included. Observed 
clinical and demographic characteristics were similar for patients initiating ART 
immediately just before and just after the guideline change in both countries (Table 7), 
therefore results presented from unadjusted regression models are assumed more valid. 
Although it does not make sense that clinicians would have been initiating fewer patients 
on tenofovir once it was available, there does appear to be a slight drop in the number of 
patients initiating ART the week immediately after the threshold, with them increasing 
again in weeks 2–4 to levels seen in the weeks prior to the guideline change in both 
countries (Figure 7). Results also show low numbers of ART initiations in January during 
the holiday period in SA. Even with these variations we believe that there is no strong 
evidence suggesting systematic manipulation of initiation dates in either country. 
The proportion of patients initiating tenofovir increased strongly in both countries 
with guidelines changes: from 7.7% to 89% in SA (risk difference (RD): 81 percentage 
points; 95% confidence interval (CI): 73 to 89), and from 7.0% to 49% in Zambia (RD: 
42 percentage points; 95% CI: 38 to 45)(Figure 7). The change in guidelines resulted in a 
decrease in single-drug substitutions in the first 24-months on ART in SA (RD: -15 
percentage points; 95% CI: -18 to -12) (Figure 8a) and a small decrease in Zambia (RD: -
2 percentage points; 95% CI: -3.6 to -0.3) (Figure 9a) at the threshold. The trends before 
and after the change in the guidelines varied. In SA, there was a high (~20%), but flat 
trend in single-drug substitutions before the threshold, then a sharp drop after that 
remained steady at about 5%. In Zambia there was far less substitution before the 
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threshold at ~10%, which slowly declined prior to the introduction of tenofovir. After the 
threshold, SDSs continued to decline to ~3%. 
Guideline change had no impact on death (RD (SA): 0.9 percentage points; 95% 
CI: -2.4 to 4.1 (Figure 8b); RD (Zambia): -1.3 percentage points; 95% CI: -3.3 to 0.8 
(Figure 9b)), attrition (RD (SA): -0.9 percentage points; 95% CI: -5.9 to 4.1 (Figure 8c); 
RD (Zambia): -1.8 percentage points; 95% CI: -3.5 to -0.1  (Figure 9c)), immunological 
response (RD (SA): -6.7 cells/uL; 95% CI: -37 to 24 cells/uL (Figure 8d)); RD (Zambia): 
-14 cells/uL; 95% CI: -42 to 15 cells/uL (Figure 9d)) or viral load failure in (RD (SA): 
2.5 percentage points; 95% CI: -0.1 to 5.0 (Figure 8e)) over the 24-months on ART at the 
threshold.  
In pooled analyses guideline change increased the proportion initiating tenofovir 
(RD: 54 percentage points; 95% CI: 51 to 57) and decreased the proportion with single-
drug substitutions (RD: -6.2 percentage points; 95% CI: -7.8 to -4.5); however, no 
difference was seen in death (RD: -0.7 percentage points; 95% CI: -2.4 to 1.1), attrition 
(RD: -0.9 percentage points; 95% CI: -2.5 to 0.6) or immune response (RD: -16 cells/uL; 
95% CI: -44 to 12 cells/uL)(Figure 11). Extending the analysis to 48 months in Zambia, 
we continued to see a small decline in single-drug substitutions (RD: -2.0 percentage 
points; 95% CI: -4.0 to -0.1); however, we still saw no effect on death, attrition or 
immune response (Figure 12). 
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DISCUSSION 
Guidelines adopting tenofovir as standard of care were rapidly implemented in 
both SA and Zambia, leading to increases in the proportion of patients initiating 
tenofovir. However, in the largest analysis to date, policy recommending initiating all 
patients on tenofovir (rather than stavudine or zidovudine) as standard of care had no 
aggregate impact on patient mortality, attrition, immunological health and viral load 
failure over 24 months on ART.  
In addition to analyzing data with wide geographic scope, our results are less 
vulnerable to major threats to validity in prior observational research on this topic [30–
36], namely the strong assumption that there is no confounding by indication. In contrast, 
our regression discontinuity approach compares outcomes in two populations, those 
initiating just before or after the guideline change, that are similar in both observed and 
unobserved factors, and differ only on the treatment available. Thus, we evaluate the 
impact of starting tenofovir for patients affected by the policy change (i.e. those who 
would not have been prioritized for tenofovir prior to the guideline change), a much 
larger group that may benefit less. We show changing guidelines caused a significant 
decrease SDSs in the first 24-months on ART in SA and a small, but significant, decrease 
in Zambia, consistent with previous observational studies [30–36]. Our results showed no 
difference in death, attrition, immune response and viral load failure, consistent with 
some studies [19, 30–32, 34, 76] but not all [30, 31]. Two studies reported stavudine was 
associated with a 30% [31] to 170% [30] increase in mortality compared to tenofovir and 
one reported a 50% increase in loss [30].   
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Our study should be considered alongside its limitations. First, although we 
believe our ITT estimates of death and attrition to be valid, due to the high rates of death, 
estimated at upwards of 50% [77], amongst patients lost from ART programs in LMICs, 
we know that we are underestimating mortality.  Second, measurements of CD4 and viral 
load were conditional on retention in care. However, bias is likely to be minimal, given 
that the guideline change induced no differences in loss. Third, the effect of the guideline 
change on SDSs did differ between countries. Although national guidelines for 
substitution of the NRTI within first-line ART were the same, the difference could be due 
to variation in monitoring practices or the availability of NRTIs for substitution. Fourth, 
our analysis would be confounded if there were other reasons for patients initiating just 
before or after the guideline change to differ systematically. In 2010 eligibility for ART 
was expanded to patients diagnosed with tuberculosis or hepatitis B virus (HBV) at ART 
initiation irrespective of CD4 count [3].  We removed patients diagnosed with 
tuberculosis at treatment initiation from our analysis, where possible. We were not, 
however, able to remove patients with HBV as testing for the virus before patients were 
initiated onto ART was limited in any African countries during the period of study [78]. 
If patients co-infected with HBV were at higher risk of single-drug substitutions then our 
results may be underestimating the effects of tenofovir in this population. There were no 
other major clinical policy changes coinciding with the change in 2010 guidelines. The 
next major WHO policy change, after April 2010, occurred in July 2011, when the CD4 
count eligibility threshold for ART increased from <200 to <350 cells/uL [1]. Further, 
our analysis revealed balance on observable characteristics among patients initiating just 
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before and after the guideline change, and we found no strong evidence of systematic 
manipulation of initiation dates. Fifth, there was a high proportion of missing observable 
characteristics. However, the proportion of missingness did not differ just above/below 
the threshold within either country, as such we would expect the missingness to be 
random at the threshold and not bias the results [74, 75]. Finally, although we analyzed 
data from the largest existing collection of HIV clinical cohorts in Southern Africa, our 
results may not be generalizable to other settings.  
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Figure 5. Regression discontinuity using complete data showing the probability of receiving tenofovir in (a) South 
Africa (n=16,179) and (b) Zambia (n=37,115) 
 
*IK Optimal Bandwith for (a) South Africa = 67.8 and (b) Zambia = 62.5 
†Risk Differences are estimated at the threshold = 0 
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Table 7. Predicted values as the date of guideline change is approached from above and below the threshold in South 
Africa and Zambia (N=52,294) 
 
Country 
Variables  
South Africa 
(n=16,179) 
Zambia 
(n=36,115) 
 
 Just above  
April 2010 
Just below 
April 2010 
p-value  
  Just above 
July 2007 
 Just below 
July 2007 
p-value  
Age (years) 36.7 36.0 0.067 34.3 34.5 0.524 
missing (n,%) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
       
Female 63.6 65.2 0.143 59.2 60.9 0.615 
missing (n,%) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
       
CD4 count (cells/uL) 155.6 163.7 0.127 193.3 186.8 0.320 
missing (n,%) 1,504 (17.3) 1,124 (15.1)  11,256 (61.6) 9,989 (56.0)  
       
Weight (kg) 64.0 64.9 0.258 53.2 52.7 0.391 
missing (n,%) 3,059 (35.1) 2,911 (39.0)  10,665 (58.4) 11,728 (65.7)  
       
Hemoglobin (g/dL) 11.0 11.2 0.332 10.8 10.8 0.986 
missing (n,%) 3,695 (42.4) 2,830 (37.9)  15,191 (83.2) 13,288 (74.4)  
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Figure 6. Number of ART initiations in South Africa (n=16,179) and Zambia (n=36,115) before and after the 
introduction of tenofovir in first-line therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Arrows in graph represent the month of January before and after the threshold in South Africa 
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Figure 7. Regression discontinuity showing the probability of receiving tenofovir in (a) South Africa (n=16,179) and (b) 
Zambia (n=36,115) 
 
*IK Optimal Bandwith for (a) South Africa = 54.7 and (b) Zambia = 104.2 
†Risk Differences are estimated at the threshold = 0 
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Figure 8. Regression discontinuity for South Africa showing a) proportion of single-drug substitution; b) proportion 
died;  c) proportion died and lost to follow-up; d) mean change in CD4 count from ART initiation and e) proportion 
viral load failure in the first 24 months on treatment (n=16,179) 
 
*IK Optimal Bandwith for (a) proportion single-drug substitution = 163.3; (b) proportion died = 145.2; (c) proportion died and lost to 
follow-up = 127.5; (d) mean change in CD4 count = 128.5 and (e) proportion viral load failure = 153.2 
†Risk Differences are estimated at the threshold = 0 
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Figure 9. Regression discontinuity for Zambia showing the a) proportion of single-drug substitution; b) proportion 
died; c) proportion died and lost to follow-up; and d) mean change in CD4 count from ART initiation in the first 24 
months on treatment (n=36,115)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*IK Optimal Bandwith for (a) proportion single-drug substitution = 158.1; (b) proportion died = 161.7; (c) proportion died and lost to 
follow-up = 270.8 and (d) mean change in CD4 count = 178.3  
†Risk Differences are estimated at the threshold = 0 
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Figure 10. Regression discontinuity showing a) proportion initiated on tenofovir; b) proportion single-drug 
substitutions; c) proportion died; d) proportion lost to follow-up and e) mean change in CD4 count from ART initiation 
for South Africa and Zambia combined in the first 24 months on treatment (n= 52,294)
 
*IK Optimal Bandwith for (a) proportion initiated on tenofovir = 98.1; (b) proportion single-drug substitution = 145.4; (c) proportion died 
= 162.2; (d) proportion died and lost to follow-up = 267.3 and (e) mean change in CD4 count = 105.0  
†Risk Differences are estimated at the threshold = 0 
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Figure 11. Regression discontinuity showing the a) proportion of single-drug substitution; b) proportion died;  c) 
proportion died and lost to follow-up; and d) mean change in CD4 count from ART initiation for Zambia in the first 48 
months on treatment (n=36,115)  
 
*IK Optimal Bandwith for (a) proportion single-drug substitution = 136.8; (b) proportion died = 198.2; (c) proportion died and lost to 
follow-up = 206.4 and (d) mean change in CD4 count = 196.8  
†Risk Differences are estimated at the threshold = 0
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CHAPTER FOUR 
 
Rapid expansion of antiretroviral therapy (ART) for treatment of HIV in low- and 
middle-income countries (LMICs) has been achieved using a “public health approach,” 
which prioritizes standardized treatment regimens that can be purchased in large 
quantities and delivered at scale [3]. As the World Health Organization (WHO) expands 
eligibility criteria for HIV care and treatment to larger populations in LMICs, the 
expectation is that programs will grow and become more reliant on large bulk purchases 
and bureaucracies, increasing the chances of breakdowns and interruptions in health care 
delivery in already overburdened health care systems.  
Since the roll-out of ART in sub-Saharan Africa there have been reports of ‘stock 
shortages’ (i.e. having less stock of a medicine available in the facility than required for 
patients until the next order is received [39]) and ‘stock outs’ (i.e. having no stock of a 
medicine which was required for patient use in that facility [39]) [39, 79–82). Despite 
being one of the wealthiest countries on the continent, South Africa has been no 
exception. South Africa has the largest number of people living with HIV, estimated at 
5.8 million, and by far the largest number of people on ART in the world (3.2 million by 
the end of 2014) [83]. In February 2012 a stock shortage of tenofovir occurred and lasted 
for roughly seven months [39]. At the time of the shortage clinicians were advised to 
place patients on stavudine or zidovudine, unless they had contraindications to the drugs, 
instead of tenofovir [84]. The expectation was that patients initiated on or switched to the 
older NRTIs (stavudine or zidovudine) during the stock shortage would substitute with 
tenofovir when it became available. During this time 20% of health facilities throughout 
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South Africa were estimated to have had either a stock shortage or stock out of tenofovir 
[39], the consequences of which have not been quantified to date.  
Previously published work in quantifying the effect of stock shortages or stock 
outs on treatment outcomes in LMICs is scare and limited, as the few existing studies 
were either conducted early on in treatment roll-out before a consistent supply of 
antiretrovirals (ARVs) had been established [79, 80] or during times of conflict [81]. A 
more recent study from Cote D’Ivoire reported ART stock outs of less common ARV 
drugs (Combivir – a fixed-dose combination nucleoside reverse transcriptase inhibitor  
(NRTI) and nevirapine – a non-nucleoside reverse transcriptase inhibitor (NNRTI)), 
affecting more than 10% of HIV-positive patients on treatment in their cohort, which 
doubled the risk of interruptions in care and death [82].  
There are many mechanisms, at the level of the provider and the patient, through 
which a stock shortage or stock out could affect HIV treatment outcomes. During a stock 
out or stock shortage of ARV drugs, care and treatment of patients could remain 
unaffected if providers had other drug options in stock to mitigate the circumstances until 
the shortage was resolved. In this scenario, treatment experienced patients and naïve 
patients could be switched to or initiated on older, but effective [19, 27], ARVs drugs 
until the shortage ended. The provider could also choose to decrease the number of pills 
dispensed during the shortage (e.g. dispensing one month to patients instead of two), 
requiring patients to return more frequently, they could refer/transfer patients to other 
clinics where drugs are available or turn patients away without drugs until the shortage 
ends. 
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At the level of the patient, a stock shortage or stock out could result in behavior 
changes that would affect adherence to care and treatment for both ART experienced and 
naïve patients. A previous study reported that stock shortages played a major role in 
patients' adherence to ART because clinic staff had to dispense fewer pills to patients, 
often borrowed from nearby clinics, or sent patients away with no drugs and asked them 
return at a later date [85]. Changes in care and treatment requiring patients to return to the 
clinic more frequently or travel longer distances to receive necessary drugs increases the 
economic burden of transport costs and the possibility of lost wages for patients, both of 
which are well known barriers of adherence to HIV care and treatment [86–88]. A change 
in behavior resulting in poor adherence to care and treatment could increase a patients’ 
risk of viral load failure, loss to follow-up and ultimately death [86–88]. 
The length of the stock shortage or stock out would be a strong determinant of the 
impact on HIV care and treatment. In the context of South Africa, the tenofovir stock 
shortage was fairly short in duration (roughly seven months) and not all clinics were 
affected [39]. Nevertheless, it is important to document and quantify the effects of a stock 
shortage on treatment outcomes to show how clinics could alter patient care to help 
individuals remain in care and on treatment during a shortage and to assess patient 
behavior and treatment outcomes in response to the modification in care and ARV 
availability. Using data from four public sector clinics in South Africa, two of which 
experienced a tenofovir stock shortage and two that did not, we investigated various 
mechanisms, at the level of the provider and the patient, to understand how the 2012 
tenofovir stock shortage affected the HIV care and monitoring of patients accessing ART.   
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METHODS 
 
Cohort Description 
This study used data from the Right to Care Clinical HIV cohort. Right to Care is 
a non-profit organization that supports HIV care and treatment services for roughly 5% of 
all HIV positive persons in South Africa at geographically dispersed clinics. The clinics 
began initiating patients onto treatment in 2004 when large-scale roll out of HIV 
treatment began in South Africa. The largest and most well described site is the Themba 
Lethu Clinic, which has initiated over 27,000 patients on treatment since 2004 [89]. The 
Right to Care Clinical HIV cohort contains data on close to 130,000 patients across seven 
clinics, over 90,000 of whom have initiated ART. Right to Care supported clinics provide 
care in accordance with the national treatment guidelines [42,90]. Each clinic collects 
patient-level data using an electronic record system (TherapyEdge-HIV™). All data, 
including demographic, clinical conditions, laboratory test results and medications (ARV 
and non-ARV related) are entered either by trained data capturers or in real-time by 
clinicians. 
Use of the Right to Care Clinical HIV cohort data was approved by the Human 
Research Ethics Committee of the University of the Witwatersrand. Approval for analysis 
of de-identified data was granted by the Institutional Review Board of Boston University. 
 
Study design 
We assessed the effect of the tenofovir stock shortage on various provider and 
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patient level mechanisms to evaluate how the shortage affected the HIV care, monitoring 
and outcomes of patients accessing ART.  Data were collected prospectively as part of 
routine care at four Right to Care supported clinics in rural Mpumalanga [91] and 
Gauteng (Themba Lethu Clinic [89] and two clinics located in Central Johannesburg 
(JHB) [92] and Northern JHB [93]). ART-naïve, HIV-infected patients >18 years of age 
who initiated first-line ART between July 1, 2011 and March 31, 2013 were included. 
The first-line ART of choice during the course of this study included the nucleoside 
reverse transcriptase inhibitor (NRTI) tenofovir (with stavudine or zidovudine, older 
NRTIs, available as alternatives) plus lamivudine (also an NRTI) and a choice of either 
efavirenz or nevirapine (non-nucleoside reverse transcriptase inhibitors (NNRTI)) [42, 
90]. 
For outcomes, we evaluated changes in number of ART initiates, time between 
pharmacy visits, transfers, single drug substitutions (defined as replacement of the NRTI 
only in first-line ART), treatment interruptions (defined as stopping the entire regimen 
for at least two weeks), missed pharmacy visits (defined as either not attending or being 
>7 days late for a scheduled pharmacy visit), loss to follow-up (>3 months late for last 
scheduled visit) and elevated viral load (defined as one viral load >1000 copies/mL [42, 
90]). 
 
Study variables 
The dates of tenofovir shortage were determined via personal communication 
with Right to Care’s head pharmacist [94] and confirmed in the clinical data. During the 
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shortage, running from February 1 2012 to August 31 2012, two of the four clinics 
included in our analysis (Rural Mpumalanga clinic and Themba Lethu Clinic) 
experienced a shortage of tenofovir, the recommended NRTI for first-line ART, and were 
providing stavudine or zidovudine for patients initiating ART. As the shortage was not 
national (only 20% of clinics were affected [39]), the other two clinics, Central and 
Northern JHB, were used for comparison as they had consistent supply of tenofovir.  
For our primary exposure, we created a variable indicating exposure to the 
tenofovir stock shortage broken down in to three periods; before (July 1 2011 January 31 
2012), during (February 1 2012 to August 31 2012) or after (September 1 2012 to March 
31 2013) the shortage. At the time of the shortage clinicians were to place all patients 
(both current patients and new initiates) on stavudine or zidovudine, unless they had 
contraindications to the drugs, instead of tenofovir and switch back to tenofovir once 
became available [84].  
 
Provider mechanisms 
To assess whether clinics made adjustments to patient care in order to mitigate the 
impact of the stock shortage we assessed the following outcomes; a) number of ART 
initiates to determine if providers were restricting the number of new patients they were 
putting on to treatment; b) time between pharmacy visits to assess if the number of pills 
dispensed decreased requiring patients to return to the clinic more frequently for drug 
pickups; c) transfers to determine if patients were being formally transferred to other 
clinics that had not experienced shortages; d) treatment interruptions (defined as stopping 
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the entire regimen for at least two weeks) to assess if patients were discontinuing therapy; 
and e) single drug substitutions (defined as replacement of the NRTI only in first-line 
ART) to assess whether providers were switching to different drugs as was 
recommended. For the outcome of single-drug substitutions, during the stock shortage the 
expectation was that patients that had been initiated or switch on to the older NRTIs 
would substitute with tenofovir when it became available. As such, we would expect 
patients on stavudine or zidovudine to experience higher rates of substitution either 
because they were taking more toxic drugs [30–38], or because clinicians were following 
the directive to switch patients to tenofovir once available.  
To determine if providers were placing patients with contraindications to 
tenofovir (such as females, patients with high body mass index or insufficient renal 
function [42, 90]) on the older NRTIs we used log-binomial regression to evaluate 
potential demographic (i.e. age and sex) and clinical (i.e. creatinine clearance levels, CD4 
count, hemoglobin levels, body mass index, WHO staging and tuberculosis) 
characteristics as predictors of not receiving tenofovir during the shortage. Creatinine 
clearance was categorized according to the U.S. National Kidney Foundation’s Kidney 
Disease Outcome Quality Initiative (K/DOQI) as normal (>90ml/min), mild (60–
89ml/min), moderate (30–59ml/min) and severe (<30ml/min) renal insufficiency [95]. 
 
Patient mechanisms  
To assess whether patient behavior or adherence to therapy changed during the 
shortage we assessed the following outcomes: a) proportion of visits missed (defined as 
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either not attending or being >7 days late for a scheduled pharmacy visit) to determine if 
the increased frequency of pharmacy visits resulted in reduced compliance with visit 
schedule; b) loss to follow-up (>3 months late for last scheduled visit) to determine if any 
patients were more likely to leave care; and c) elevated viral load (defined as one viral 
load >1000 copies/mL [42, 90]) as an indicator of adherence to treatment. We also 
assessed the effect on mortality and CD4 response in our analysis and, as expected due to 
the length of follow-up, we found no effect of the stock shortage on these outcomes and 
did not report them here.  
 
Statistical analysis 
Patient demographic and clinical characteristics at ART initiation were 
summarized with descriptive statistics and stratified by the three time periods; before 
(July 1 2011 January 31 2012), during (February 1 2012 to August 31 2012) or after 
(September 1 2012 to March 31 2013) the stock shortage. For both provider and patient 
level outcomes we used linear regression to fit splines with knots at the beginning 
(February 1 2012) and end (August 31 2012) of the tenofovir stock shortage and 
displayed results graphically by clinic to show trends over time. We fit lines between the 
knots for the outcomes of number of ART initiates and days between pharmacy visits as 
they are absolute values aggregated by calendar month for each clinic, while we fit 
curves for all other outcomes as they were binary and measured at the level of the 
individual.  
Since we have three time periods (before, during and after the shortage), we used 
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difference-in-difference models to estimate risk differences (RD) and corresponding 95% 
confidence intervals (CI) to assess the effect of exposure to the stock shortage on all 
outcomes. Each outcome was regressed on an indicator of time (before, during and after 
the stock shortage), an indicator for clinics exposed to the stock shortage (rural 
Mpumalanga clinic and Themba Lethu Clinic) or not exposed (Central JHB and Northern 
JHB clinics), demographic (i.e. age, sex and clinic) and clinical (i.e. CD4 count, 
hemoglobin levels, body mass index, WHO staging, tuberculosis and non-nucleoside 
reverse transcriptase inhibitor (NNRTI) (nevirapine or efavirenz) used in first-line 
regimen) characteristics at ART initiation.  
  
RESULTS  
In total, 10,895 treatment naïve non-pregnant, patients >18 years of age initiated a 
standard first-line ART regimen between July 1, 2011 and March 31, 2013. At ART 
initiation patients had a median CD4 count of 177 cells/mm3 (IQR: 83–273 cells/mm3), 
were predominately female (60.6%), had a median age of 36.8 years (interquartile range 
(IQR): 30.7–43.8 years). When stratified into the three time periods and by clinic, 
patients attending clinics before, during or after the shortage were similar on 
demographic and clinical characteristics within clinics (Table 8).  
 
Tenofovir stock shortage 
Table 8 and Figure 13, which shows the trend in the proportion of initiating 
tenofovir over the follow-up period for each clinic, shows that during the stock shortage, 
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upwards of 70% of patients initiating ART at the rural Mpumalanga clinic and 20% of 
patients at Themba Lethu Clinic were being initiated on a stavudine- or zidovudine-based 
regimen, instead of tenofovir, substantially higher than before or after the shortage. Over 
the entire time period of study the control clinics (Central JHB and Nothern JHB) showed 
no temporal trend in tenofovir use.  
 
Provider mechanisms 
We also assessed if clinics modified patient care and treatment during the stock 
shortage to mitigate its impact on outcomes. We found a slight decline in the number of 
patients initiating ART during the period of the tenofovir shortage (Figure 14), with the 
greatest decline in the number of new initiates at Themba Lethu Clinic. However, the 
decline at Themba Lethu began prior to the stock shortage and continued in the period 
after, suggesting it may have had little to do with the shortage itself.  We saw a decrease 
in average days between pharmacy visits during the shortage (Figure 15). Prior to the 
shortage there were roughly 50 days between visits, which decreased to about 35 days 
during the shortage and increased back to 50 days after the shortage was resolved. In 
addition we found no significant difference in the trends in the proportion of patients 
needing a single-drug substitution at all four clinics (Figure 16) and little evidence that 
the shortage impacted transfers to other facilities or treatment interruptions as trends 
remained roughly constant over the period of follow-up (Figures 17 and 18). Results of 
our difference-in-difference models showed little impact on these outcomes during the 
period of the stock shortage compared to before when accounting for overall trends 
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(Table 9). We did, however, see a small but significant increase in the risk of transfer 
(RD: 0.8%; 95% CI: 0.5%, 1.0%) and a small but significant decrease in the risk of 
single-drug substitutions (RD: -1.6; 95% CI: -2.7%, -0.5%) after the shortage compared 
to before (Table 9) 
When evaluating whether or not clinics were prioritizing certain patients for 
tenofovir during the stock shortage. We found that patients with mild (60–89ml/min) 
(risk ratio (RR): 1.75; 95% CI: 1.40, 2.18) to moderate/severe (<60ml/min) (RR: 5.39; 
95% CI: 4.28, 6.80) renal insufficiency (measured by creatinine clearance levels) were at 
increased risk of not receiving tenofovir during the shortage compared with those that 
had normal creatinine clearance levels (>90ml/min) (Table 10). We also found that males 
(vs. females) and those with low hemoglobin levels (<10 ug/dL vs. >10 ug/dL) were at 
increased risk of not receiving tenofovir during the shortage. 
 
Patient mechanisms 
We assessed whether patient behavior and adherence to ART (as measured by a 
detectable viral load) changed during the stock shortage. We found no variation in loss to 
follow-up (Figure 19), while there is some suggestion that the trend in the proportion of 
patients experiencing an elevated viral load increased after the shortage (Figure 20). 
However, the trend occurred in all four clinics suggesting that it may not be due to the 
stock shortage. We also found an increase in the proportion of patients at the rural 
Mpumalanga clinic having a missed pharmacy visit during (~20%) the stock shortage 
period compared to before (~10%) (Figure 21). Difference-in-difference analysis 
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confirmed an increase in missed pharmacy visits during the shortage, showing a small 
risk difference of 1.2% (95% CI: 0.5%, 2.0%) (Table 9).   
 
DISCUSSION 
Our study is the first to quantify the effects of a substantial tenofovir stock 
shortage in South Africa on provider and patient mechanisms and describe subsequent 
outcomes in HIV-positive adults at four large public sector HIV clinics. While imprecise, 
our results suggest a potential shift in how providers managed patients during the period 
of the shortage, mainly, a noticeable decrease in the average number of days between 
visits during the shortage compare to before or after at all four clinics. The decrease in 
number of days across all clinics could be cyclical due to the time of year and unrelated 
to the stock shortage, due to Right to Care supported clinics receiving a smaller supply of 
drugs until the shortage was resolved or a clinic decision to dispense fewer pills at each 
drug pick-up visit until the shortage was resolved. We found that clinicians continued to 
follow national guidelines [42, 90] during the stock shortage as patients with poor renal 
function and those with low hemoglobin levels were less likely to receive tenofovir 
during the shortage. All other provider level outcomes remained consistent across the 
study period. 
With regards to behavior change at the patient level as a result of the shift in 
provider management of patients, we found no evidence of an increase in loss to follow-
up; however, there was an increase in the proportion of patients missing pharmacy visits. 
This was mainly driven by one site located in rural Mpumalanga Province, where we saw 
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roughly 10% of patients missing a visit prior to the stock shortage, a proportion that 
doubled during and after the stock shortage. Previous research has shown that the type of 
community (urban vs. rural) can be a factor of adherence to HIV care and treatment, due 
to differences in community characteristics such as, density of population, distance to and 
availability of clinics and hospitals and infrastructure within clinics [96,97].  
There is evidence, albeit limited, that HIV patients receiving ART exposed to 
ARV stock shortages or stock outs (vs. those unexposed) in LMICs have an increased 
risk of virologic failure and attrition [79–81]. Our results, which show no impact of the 
shortage on loss to follow-up and viral load status, may be related to the fact that there 
was a stock shortage of tenofovir a not a complete stock out. As such, clinics had access 
to stavudine and zidovudine during that period allowing them to continue to initiate new 
patients while maintaining treatment experienced patients on tenofovir during the 
shortage. We also note that previous research has shown that death, loss to follow-up, 
immune response and viral load suppression are comparable for patients taking stavudine, 
zidovudine or tenofovir [19, 27, 30–38], suggesting that as long as care and monitoring of 
patients remain consistent, there should be little impact on these outcomes.  
Access to one of the largest HIV clinic cohorts in South Africa that has been 
actively enrolling patients since the roll-out of treatment in the country in 2004 provided 
us an opportunity to evaluate the effect of the tenofovir shortage on provider and patient 
level outcomes in multiple public-sector urban and rural clinics. However, our findings 
should be considered alongside potential limitations. First, this study represents patients 
from public sector clinics supported by an NGO partner, and may, therefore, not be 
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generalizable to other clinics or settings. Second, as data on pre-ART care is poorly 
captured in HIV care in LMICs, we were unable to show if the shortage affected patients 
who had not yet initiated ART. Third, due to the short period of follow-up we may have 
missed more subtle or longer-term effects that may be picked up later. Lastly, previous 
research reported conflict as a reason for ARV stock shortage or stock out [81], which 
was not the case at Right to Care supported sites, making our results less generalizable to 
conflict settings.  
 
Conclusion 
When health facilities lack the necessary drugs to treat HIV effectively, patients 
are at increased risk of developing and transmitting drug resistance strains, interrupting or 
defaulting on treatment, and ultimately increased risk of morbidity and mortality. While 
South Africa has made great strides to extend access to ART as well as increase the 
quality of the health services provided, patient care can be affected when stock 
shortages/outs occur. While our results show little effect on treatment outcomes when 
comparing patients accessing care during the shortage to those accessing care outside 
periods of shortage, this most likely reflects the clinics’ ability to mitigate the crisis by 
continuing to keep patients care and treatment as consistent as possible. 
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Table 8. Demographic and clinical characteristics of patients stratified by if they attended the clinic before, during or 
after the period of shortage at 4 HIV clinics in South Africa (n=10,895) 
  
Patients  
 Jul. 1 2011  
to Feb. 1 2012  
Patients 
Feb. 2 2012  
to Sep. 01 2012 
Patient  
Sep. 1 2012  
to Mar. 31 2013 
All patients 
included 
  Rural Mpumalanga Clinic 
  n=479 n=345 n=219 n=1043 
NRTI   tenofovir, n(%) 443 (93.5) 127 (36.8) 196 (89.5) 766 (73.4) 
NNRTI efavirenz, n(%) 467 (97.5) 328 (95.1) 211 (96.4) 1006 (96.5) 
gender female, n(%) 297 (62.0) 217 (62.9) 143 (65.3) 657 (63.0) 
WHO Stage III/IV, n(%) 104 (21.7) 70 (20.3) 54 (24.7) 228 (21.9) 
tuberculosis yes, n(%) 30 (6.3) 14 (4.1) 21 (9.6) 65 (6.2) 
age (years) median (IQR) 38.5 (32.0–47.2) 38.5 (31.7–46.1) 38.6 (31.9–46.2) 38.5 (31.9–46.6) 
CD4 count (cells/uL) median (IQR) 178.5 (73.0–273.0) 277.3 (184.9–338.7) 239.0 (119.0–340.0) 215.5 (116.0–308.0) 
body mass index (kg/m
2
) median (IQR) 21.3 (18.6–25.0) 21.5 (18.5–25.3) 22.7 (19.2–25.9) 21.8 (18.7–25.4) 
hemoglobin (ug/dL) median (IQR) 11.1 (9.4–12.2) 11.5 (9.7–12.9) 11.1 (9.1–12.7) 11.2 (9.5–12.6) 
  Themba Lethu Clinic 
  n=1781 n=1767 n=928 n=4476 
NRTI   tenofovir, n(%) 1605 (90.1) 1411 (79.9) 769 (82.9) 3785 (84.6) 
NNRTI efavirenz, n(%) 1647 (92.5) 1679 (95.0) 881 (94.9) 4207 (94.0) 
gender female, n(%) 1049 (58.9) 1074 (60.8) 537 (57.9) 2660 (59.4) 
WHO Stage III/IV, n(%) 413 (23.2) 385 (21.8) 188 (20.3) 986 (22.0) 
tuberculosis yes, n(%) 146 (8.2) 115 (6.5) 52 (5.6) 313 (7.0) 
age (years) median (IQR) 37.8 (31.7–44.9) 37.9 (31.6–44.4) 37.7 (31.5–45.1) 37.8 (31.6–44.8) 
CD4 count (cells/uL) median (IQR) 164.0 (73.0–249.0) 179.0 (72.0–281.0) 156.0 (57.0–277.0) 168.0 (70.0–268.0) 
body mass index (kg/m
2
) median (IQR) 22.3 (19.5–26.1) 22.3 (19.8–26.2) 22.8 (19.5–26.2) 22.4 (10.7–26.2) 
hemoglobin (ug/dL) median (IQR) 11.9 (10.4–13.4) 12.2 (10.4–13.6) 12.4 (10.6–13.8) 12.1 (10.5–13.5) 
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Patients  
 Jul. 1 2011  
to Feb. 1 2012  
Patients 
Feb. 2 2012  
to Sep. 01 2012 
Patient  
Sep. 1 2012  
to Mar. 31 2013 
All patients 
included 
  Northern JHB Clinic 
  n=859 n=988 n=778 n=2625 
NRTI   tenofovir, n(%) 784 (91.3) 898 (90.9) 727 (93.4) 2409 (91.8) 
NNRTI efavirenz, n(%) 769 (89.5) 866 (87.7) 726 (93.3) 2361 (90.0) 
gender female, n(%) 516 (60.1) 658 (66.6) 467 (60.0) 1641 (62.5) 
WHO Stage III/IV, n(%) 214 (24.9) 138 (14.0) 87 (11.2) 439 (16.7) 
tuberculosis yes, n(%) 71 (8.3) 47 (4.8) 23 (3.0) 141 (5.4) 
age (years) median (IQR) 36.4 (30.6–43.4) 36.7 (30.7–43.4) 35.4 (30.0–42.3) 36.2 (30.4–43.1) 
CD4 count (cells/uL) median (IQR) 136.0 (67.0–196.0) 190.0 (103.0–263.0) 176.0 (81.0–268.0) 165.0 (82.0–248.0) 
body mass index (kg/m
2
) median (IQR) 23.2 (20.3–26.9) 24.8 (21.6–29.2) 24.7 (22.0–28.7) 24.4 (21.4–28.4) 
hemoglobin (ug/dL) median (IQR) 11.8 (10.2–13.3) 12.1 (10.6–13.6) 11.9 (10.5–13.4) 11.9 (10.5–13.4) 
  Central JHB Clinic 
  n=998 n=946 n=807 n=2751 
NRTI   tenofovir, n(%) 902 (90.4) 847 (89.5) 720 (89.2) 2469 (89.8) 
NNRTI efavirenz, n(%) 937 (93.9) 895 (94.6) 772 (95.7) 2604 (94.7) 
gender female, n(%) 643 (64.4) 625 (66.1) 549 (68.0) 1817 (66.1) 
WHO Stage III/IV, n(%) 249 (25.0) 189 (20.0) 180 (22.3) 618 (22.5) 
tuberculosis yes, n(%) 116 (11.6) 97 (10.3) 103 (12.8) 316 (11.5) 
age (years) median (IQR) 35.6 (29.8–42.2) 35.2 (29.9–41.7) 34.4 (28.8–40.1) 35.1 (29.5–41.6) 
CD4 count (cells/uL) median (IQR) 177.0 (90.0–280.0) 199.0 (97.0–286.0) 207.0 (108.0–326.0) 193.0 (96.0–294.0) 
body mass index (kg/m
2
) median (IQR) 23.4 (20.9–27.0) 23.9 (21.0–27.9) 23.7 (20.7–27.7) 23.6 (20.9–27.6) 
hemoglobin (ug/dL) median (IQR) 11.8 (10.2–13.3) 11.9 (10.4–13.2) 11.7 (10.3–13.1) 11.7 (10.3–13.2) 
 
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; World Health Organization, 
WHO
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Figure 12. Trends in the proportion of HIV-positive patients initiating tenofovir at four government sector clinics in South Africa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
**transformation regression models run using PROC TRANSREG in SAS
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Figure 13. Trends in the absolute numbers of HIV-positive patients initiating ART at four government sector clinics in South 
Africa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Figure 14. Trends in the average number of days between pharmacy visits in four government sector clinics in South Africa.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Figure 15. Trends in the proportion HIV-positive patients experiencing a single-drug substitution in four government sector Right 
to Care clinics, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Figure 16. Trends in the proportion HIV-positive patients transferred out in four government sector Right to Care clinics, South 
Africa. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Figure 17. Trends in the proportion HIV-positive patients experiencing a treatment interruption in four government sector Right 
to Care clinics, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Table 9. Difference-in-difference models assessing provider and patient level 
mechanisms on treatment outcomes during and after the stock shortage compared 
to before in the Right to Care Clinical HIV cohort, South Africa  
 Provider Level  
 Number of  
ART 
 initiates 
(95% CI)* 
Mean days 
 between 
pharmacy 
visits 
(95% CI)* 
Transfers 
Adjusted* 
RD (95% CI) 
Single-drug 
 substitution 
Adjusted*  
RD (95% CI) 
Treatment  
interruptions 
Adjusted*  
RD (95% CI) 
Time       
before Reference Reference Reference Reference Reference 
during -19.0 (-88.5–50.5) -4.7 (-11.6, 2.2) -0.2 (-0.5, 0.0) -0.6 (-1.3, 0.1) -1.6 (-3.7, 0.5) 
after -63.5 (-138.3–11.2) -2.1 (-9.8, 5.7) 0.8 (0.5, 1.0) -1.6 (-2.7, -0.5) -1.4 (-4.4, 1.6) 
 Patient Level  
 Loss to  
follow-up 
Adjusted*  
RD (95% CI) 
Missed  
visits 
Adjusted* 
 RD (95% CI) 
Elevated  
viral load 
Adjusted*  
RD (95% CI) 
Time     
before Reference Reference Reference 
during -0.2 (-0.5, 0.1) 1.2 (0.5, 2.0) 0.0 (-1.2, 1.2) 
after -0.4 (-0.6, -0.1) 2.4 (1.6, 3.2) -0.3 (-1.9, 1.3) 
*Models also adjusted for nucleoside reverse transcriptase inhibitor, non-nucleoside reverse 
transcriptase inhibitor, gender, age, World Health Organization stage, CD4 count, body mass 
index and hemoglobin levels at ART initiation. 
Risk Difference, RD 
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Table 10. Estimated risk ratios at ART initiation of not receiving tenofovir during 
the tenofovir shortage in Right to Care Clinical HIV cohort, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Crude Risk Ratio  
(95% CI) 
Adjusted Risk Ratio 
(95% CI) 
creatinine clearance   
normal Reference Reference 
mild 1.72 (1.40–2.10) 1.75 (1.40–2.18) 
moderate/severe 5.39 (4.49–6.46) 5.39 (4.28–6.80) 
gender   
female Reference Reference 
male 1.14 (0.95–1.36) 1.24 (1.05–1.46) 
age    
<25 1.19 (0.82–1.73) 1.42 (0.97–2.07) 
25–29.9 1.02 (0.77–1.36) 1.10 (0.83–1.46) 
30–39.9 Reference Reference 
40–49.9 1.25 (1.01–1.55) 1.06 (0.87–1.31) 
>50 1.73 (1.36–2.20) 1.03 (0.81–1.31) 
WHO stage   
I/II Reference Reference 
III/IV 1.08 (0.86–1.32) 0.90 (0.72–1.13) 
CD4 count (cells/mm
3
)   
>200 Reference Reference 
101–200 0.87 (0.70–1.08) 0.82 (0.67–1.01) 
50–100  0.89 (0.66–1.20) 0.76 (0.57–1.00) 
<50 0.89 (0.68–1.16) 0.79 (0.61–1.03) 
tuberculosis   
no Reference Reference 
yes 0.84 (0.58–1.22) 0.90 (0.61–1.34) 
body mass index (kg/m
2
)   
>18.5 Reference Reference 
<18.5 1.82 (1.48–2.24) 1.09 (0.89–1.35) 
hemoglobin (ug/dL)   
>10 Reference Reference 
<10 1.27 (1.03–1.56) 1.26 (0.99–1.54) 
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Figure 18. Trends in the proportion HIV-positive patients lost to follow-up in four government sector Right to Care clinics, South 
Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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 Figure 19. Trends in the proportion HIV-positive patients experiencing an elevated viral load in four government sector Right to 
Care clinics, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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Figure 20. Trends in the proportion HIV-positive patients with missed visits in four government sector Right to Care clinics, 
South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*red vertical bars represent the time period of the tenofovir stock shortage 
** transformation regression models run using PROC TRANSREG in SAS 
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CHAPTER FIVE 
These three studies advance the understanding of the impact of WHO policy 
changes substituting the NRTI stavudine with zidovudine or tenofovir in first-line ART 
across multiple countries throughout sub-Saharan Africa, in addition to assessing the 
effect of tenofovir stock shortages on treatment outcomes in South Africa. These findings 
have clinical importance and suggest further research questions surrounding the choice of 
NRTI in first-line ART and the effect of stock shortages on HIV patient outcomes.  
In LMICs clinical guidelines are often implemented at scale based on positive 
experiences in sub-populations of patients. However, the benefits of interventions may 
differ across populations, and the trade-offs between targeted and population-wide 
approaches should be considered. As such, evaluations of policy changes are critical to 
inform future policy revisions, optimize resource allocation and maximize the health 
benefits for patients on ART. Additionally, evaluation will help to inform policy in 
LMICs that have yet to include zidovudine or tenofovir in first-line ART or those that 
have made the change but phase out of stavudine is slow due to cost.  
Studies 1 and 2 provide strong evidence of the impact of the WHO policy 
substituting stavudine with zidovudine or tenofovir in sub-Saharan Africa. Study 1 
demonstrates that the decline in single-drug substitutions in the first 24 months on 
treatment is associated with phasing out of stavudine for zidovudine or tenofovir in the 
Southern, Western and Eastern regions of Africa. In addition to showing that patients on 
zidovudine or tenofovir have a lower rate of single-drug substitutions compared to 
patients on stavudine. In Study 2 we used a novel regression discontinuity design, a 
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quasi-experimental method that minimizes confounding, to compare outcomes in patients 
presenting just before/after guideline changes using. When the WHO recommended that 
all patients initiate tenofovir, it was in hopes that it would lead to improved adherence 
and reduced lost to follow-up [3], with implications for longer-term health outcomes, 
such as CD4 recovery, viral suppression and survival. However, the benefits of tenofovir 
over 24 and 48 months of follow-up are likely smaller than originally anticipated. We 
found no evidence that a blanket policy initiating all patients on tenofovir has had any 
impact on these outcomes relative to the prior policy of switching patients to tenofovir if 
they experienced adverse reactions to their initial regimen. The guideline change did, 
however, prevent months of toxicities/side effects for the 10% and 20% of patients in 
Zambia and South Africa, respectively, who were ultimately switched prior to 2010. 
Further, there may have been reductions in toxicities related to stavudine and other 
aspects of morbidity, which may not have led to single-drug substitutions, but would 
have reduced quality of life for patients on ART.  
In Study 3 we sought to investigate, for the first time, various mechanisms, at the 
level of the provider and the patient by which the 2012 tenofovir stock shortage might 
have affected the HIV care and monitoring of patients accessing ART. When health 
facilities lack the necessary drugs to treat HIV, patients are at increased risk of 
developing drug resistance, interrupting or defaulting on treatment, and ultimately 
morbidity and mortality. While South Africa has made great strides to extend access to 
ART as well as increase the quality of the services it provides patients, patient care can 
be affected when stock outs occur. While our results show little effect on treatment 
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outcomes when comparing patients accessing care during the shortage, this most likely 
reflects the ability of Right to Care to mitigate the crisis by continuing to keep patients 
care and treatment as consistent as possible. 
Great strides have been made to extend access to ART as well as increase the 
quality of the services provided to patients in sub-Saharan Africa. Continued access to 
and a consistent supply of tenofovir in this setting is necessary for patients to receive 
drugs that are comparable to those used for HIV treatment in high-income countries, as 
we show that phasing out of stavudine and for either zidovudine or tenofovir potentially 
reduced toxicities and improved quality of life in multiple regions throughout sub-
Saharan Africa. While we show little effect on treatment outcomes when comparing 
patients accessing care and treatment during the shortage of tenofovir compared to those 
that did not, this most likely reflects the clinics’ ability to offset the crisis at affected 
clinics by continuing to initiate newly diagnosed and eligible patients on treatment and 
keep treatment experienced patients on their current regimen. 
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